EP4069082B1 - Techniques et dispositifs de fourniture d'adaptabilité et de personnalisation dans le traitement du diabète - Google Patents

Techniques et dispositifs de fourniture d'adaptabilité et de personnalisation dans le traitement du diabète Download PDF

Info

Publication number
EP4069082B1
EP4069082B1 EP20830426.1A EP20830426A EP4069082B1 EP 4069082 B1 EP4069082 B1 EP 4069082B1 EP 20830426 A EP20830426 A EP 20830426A EP 4069082 B1 EP4069082 B1 EP 4069082B1
Authority
EP
European Patent Office
Prior art keywords
insulin
blood glucose
carbohydrate ratio
correction factor
user
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP20830426.1A
Other languages
German (de)
English (en)
Other versions
EP4069082A1 (fr
Inventor
Yibin Zheng
Joon Bok Lee
Steven Cardinali
Jason O'connor
Eric Benjamin
Ian Mclaughlin
David Nazzaro
Ashutosh ZADE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Insulet Corp
Original Assignee
Insulet Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insulet Corp filed Critical Insulet Corp
Priority to EP24159863.0A priority Critical patent/EP4354455B1/fr
Priority to EP25209420.6A priority patent/EP4657456A3/fr
Publication of EP4069082A1 publication Critical patent/EP4069082A1/fr
Application granted granted Critical
Publication of EP4069082B1 publication Critical patent/EP4069082B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
    • A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
    • A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
    • A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
    • A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7271—Specific aspects of physiological measurement analysis
    • A61B5/7282—Event detection, e.g. detecting unique waveforms indicative of a medical condition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
    • A61M5/14248—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body of the skin patch type
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/60—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to nutrition control, e.g. diets
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/40—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management of medical equipment or devices, e.g. scheduling maintenance or upgrades
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
    • G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
    • G16H40/67—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
    • A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
    • A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
    • A61M2005/1726—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure the body parameters being measured at, or proximate to, the infusion site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/50—General characteristics of the apparatus with microprocessors or computers
    • A61M2205/502—User interfaces, e.g. screens or keyboards
    • A61M2205/505—Touch-screens; Virtual keyboard or keypads; Virtual buttons; Soft keys; Mouse touches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/50—General characteristics of the apparatus with microprocessors or computers
    • A61M2205/52—General characteristics of the apparatus with microprocessors or computers with memories providing a history of measured variating parameters of apparatus or patient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00—Measuring parameters of the user
    • A61M2230/20—Blood composition characteristics
    • A61M2230/201—Glucose concentration

Definitions

  • Insulin pumps and diabetes management devices to calculate the amount of insulin to be delivered to a user are known in the art, see e.g. US 2014/276556 A1 , US 2005/192494 A1 , US 2012/226259 A1 and US 2009/018406 A1 .
  • An insulin-carbohydrate (IC) ratio which is conversion factor of number of carbohydrates to units of insulin to be delivered, enables a user or a diabetes management device to calculate an amount of insulin to be delivered when about to eat a meal or after eating a meal.
  • This IC ratio may be periodically tuned.
  • an adjustment to a user's insulin-carbohydrate (IC) ratio is a physician modification of the IC ratio after a manual review of each person's blood glucose measurement and insulin delivery histories, which may occur after as long as 3-6 months between physician visits. It would be beneficial if an artificial pancreas algorithm were operable to adjust the IC ratio on a more regular basis.
  • the artificial pancreas (AP) application when executed by a processor may enable a system to monitor a user's glucose values, determine an appropriate level of insulin for the user based on the monitored glucose values (e.g., blood glucose concentrations or blood glucose measurement values) and other information, such as user-provided information, such as carbohydrate intake, exercise times, meal times or the like, and take actions to maintain a user's blood glucose value within an appropriate range.
  • the appropriate blood glucose value range may be considered a target blood glucose value of the particular user.
  • a target blood glucose value may be acceptable if it falls within the range of 80 mg/dL to 120 mg/dL, which is a range satisfying the clinical standard of care for treatment of diabetes.
  • this adjustment may be conducted once per day or less frequently.
  • the intensity of these adjustments may be modified based on the value of the blood glucose measurement values.
  • the processor executes programming code, such as an artificial pancreas application, stored in a memory accessible by the processor.
  • the processor when executing the programming code is operable to perform various functions.
  • the various functions include obtaining a prior insulin-carbohydrate ratio (e.g., IC old ) (110) from a memory, via an input to an input device coupled to the processor, or, via a communication from an external source, such as a cloud-based diabetes treatment plan management system or the like.
  • the prior insulin-carbohydrate ratio may be stored in a memory, such as, for example, in a settings file or the like coupled to the processor that is used by the artificial pancreas application in the calculation of dosage settings by the artificial pancreas application.
  • a processor may receive blood glucose measurement values from a continuous glucose monitor or the like.
  • the processor monitors the received blood glucose measurement values to determine the number of received blood glucose measurement values that are below a hypoglycemic threshold value (e.g., less than 70 mg/dL).
  • the processor may, as part of the monitoring, compare each received blood glucose measurement value to a hypoglycemic threshold value and increment a hypoglycemia counter if the received blood glucose measurement value is below the hypoglycemic threshold value.
  • the processor determines a hypoglycemia IC correction factor based on the monitored number of blood glucose measurements below the hypoglycemic threshold.
  • the hypoglycemia IC correction factor may be used to increase the new IC ratio if an amount of time that blood glucose measurements are below the hypoglycemic blood glucose measurement value, e.g., less than 70 mg/dL, which is a clinical threshold value for hypoglycemia.
  • the monitored number may be converted into a time parameter. For example, the monitored number of blood glucose that are below the hypoglycemic blood glucose measurement value may be multiplied by 5 minutes, which is the amount of time between blood glucose measurements.
  • the processor monitors the number of blood glucose measurement values that exceed a hyperglycemia threshold. For example, the processor may monitor the received blood glucose measurement values to determine the number of received blood glucose measurement values that exceed a hyperglycemic threshold value (e.g., greater than 180 mg/dL). For example, the processor, as part of the monitoring, may compare each received blood glucose measurement value to a hyperglycemic threshold value and increment a hyperglycemia counter if the received blood glucose measurement value is greater than the hyperglycemic threshold value.
  • a hyperglycemic threshold value e.g., greater than 180 mg/dL
  • the processor determines a hyperglycemia IC correction factor based on the monitored number of blood glucose measurements that exceed a hypoglycemic threshold (150).
  • the hyperglycemia IC correction factor may be used to reduce the new IC ratio if the amount of time that the blood glucose measurements are above the hyperglycemia blood glucose measurement value, e.g., greater than 180 mg/dL, which is a clinical threshold for hyperglycemia.
  • the processor monitors the number of times (or amount of time) the artificial pancreas application was in a suspend insulin delivery status. For example, the artificial pancreas application may determine that the delivery of insulin has exceeded their needs so a processor executing the artificial pancreas application may suspend the delivery of insulin including basal insulin doses.
  • the artificial pancreas application may monitor the number of times or the total time that the delivery of insulin is suspended either by a user input or by a suspend delivery process determination made by the artificial pancreas application.
  • the artificial pancreas application may be operable to determine an amount of insulin a person has in their body, referred to as insulin onboard (IOB).
  • IOB insulin onboard
  • the IOB may be determined a number of ways and may be based on amounts of insulin delivered, a user's insulin sensitivity, duration of insulin action and the like. If the IOB is too great, the artificial pancreas application may suspend further delivery of insulin to prevent a user's blood glucose measurement values from falling outside the range of 70 mg/dL - 180 mg/dL.
  • the predetermined period to time may be 30 minutes, 1 hour, 4 hours, or longer.
  • the processor may keep track of the number of times N insulin delivery is suspended, for example, based on the number of times that the suspend delivery signal was initiated or received over a given period of time (e.g., 72 hours or the like).
  • a given period of time e.g., 72 hours or the like.
  • an amount of time in which the delivery of insulin was suspended may be determined and may be used to determine a third factor in the IC ratio adjustment as shown in the third parenthetical of Equation No. 1 above.
  • Pharmacokinetics (PK) and pharmacodynamics (PD) of the drug with respect to the user may be relevant to the third and fourth parenthetical factors.
  • the processor determines a suspend IC correction factor based on the number of times in which the artificial pancreas application was in the suspend insulin delivery status.
  • the determined value of the suspend IC correction factor in the third parenthetical may be used to increase the IC ratio so that future instances of over-delivery are reduced.
  • 1 + ⁇ i 1 N t suspend N 72 .
  • the variable t suspend i.e., Tsuspend
  • N may refer to the number of times the suspend delivery signal was received.
  • the processor further monitors a number of insulin doses delivered in which the amount of insulin in the delivered dose exceeded a basal insulin dosage setting at the time the insulin dose was delivered (180). For example, a basal insulin dose may be 0.5 U/hour, while the actual delivered dosage was 1.5 U/hour.
  • the artificial pancreas application executing on the processor is operable to determine an over-basal IC correction factor based on the monitored number of insulin doses delivered in which the amount of insulin in the delivered dose exceeded a basal insulin dosage setting (185).
  • the over-basal IC factor in the fourth parenthetical is an indication of under-delivery if the algorithm is frequently delivering over the user's basal profile.
  • the artificial pancreas application is delivering insulin above the basal threshold, the artificial pancreas application is attempting to compensate for the user's increased glucose needs. Therefore, the IC ratio may be decreased based on the time that the automatic insulin delivery as controlled by the artificial pancreas application is delivering more insulin than the user's basal needs.
  • the artificial pancreas application executing on the processor calculates a new IC ratio (i.e., IC new1 ).
  • the new IC ratio, ICnewl may be based on the prior IC ratio, the determined hypoglycemia IC correction factor, the determined hyperglycemia IC correction factor, the determined suspend IC correction factor, and the determined over-basal IC correction factor, as shown in Equation No. 1.
  • the artificial pancreas application may determine a new insulin dosage for the next delivery of insulin using the new IC ratio (i.e., IC new1 ).
  • the artificial pancreas application actuates delivery of a next insulin dose based on a calculated insulin dosage using the calculated new IC ratio (195).
  • the respective factors included a post prandial period factor of 72.
  • the post prandial period factor of 72 is based on 6 hours of a post prandial period.
  • the post prandial factor may be calculated as 6 hours times 12 blood glucose measurements per hour (every 5 minutes) equals 72).
  • the post prandial period factor may be adjusted or tuned for the proper prandial period as needed.
  • the 6 hours may be considered a basis for delivered insulin action.
  • a post prandial period other than 6 hours may be used. For example, 12 hours, 3 hours or the like may be used depending on the meal (e.g., breakfast may be one time period, while lunch or dinner may be a different period of time).
  • hypoglycemia IC correction factor and the hyperglycemia IC correction factor may be used with or without an automatic insulin delivery (AID) algorithm such as that provided by an artificial pancreas application.
  • AID automatic insulin delivery
  • the suspend IC correction factor and the over-basal IC correction factor may also be used.
  • the IC ratio modification may be based on known blood glucose measurement values and insulin onboard (IOB) traces.
  • the IOB may BE used to estimate how much insulin is in a user's body.
  • an insulin dosage recommendation may be 10 units of insulin.
  • the user may have 3 units of IOB.
  • the dosage recommendation may be reduced by simple subtraction from 10 units of insulin to 7 units of insulin (10 units of recommended dosage minus 3 units of IOB (which the body still needs to process)).
  • the user's post prandial blood glucose measurements and insulin traces can be correlated to determine if the IOB values sufficiently compensate for the resulting glucose excursions following the meals.
  • This correlation can then be utilized to identify the correct IC ratios based on known user input values.
  • this IC estimate can be calculated for each meal that is ingested and provide an IC ratio profile that is customized to each user's meal.
  • the numerator is a calculation of the amount of insulin that a user needs in the post prandial period (e.g., 6 hours after a meal) to compensate for the meal.
  • the first term in the numerator, the IOB post prandial term is the amount of insulin that a user has received during the post prandial period.
  • insulin delivery correction term is an amount of insulin that would have enabled the user to meet their target blood glucose setting.
  • the insulin delivery correction term may either be positive (meaning the user could have used more insulin) or negative (meaning the user could have used less insulin).
  • the denominator is the amount of carbohydrates that were in a meal which is represented by the variable CHO meal . This equation (i.e., Equation No. 2) provides the IC ratio (insulin over carbohydrates) that provides the ICnew2.
  • This process may be done for each meal until there is a convergence to an optimal IC ratio.
  • FIG. 1C A process example illustrating the implementation of the Equation No. 2 is shown in FIG. 1C .
  • the artificial pancreas application executing on a processor 161 may receive, at 161, an approximate amount of carbohydrates ingested in a meal or to be ingested in a meal (162).
  • the artificial pancreas application may keep track or monitor the delivery of insulin over a period of time once it is determined that a meal is ingested, or to be ingested (163). For example, after users indicate a meal ingestion through the request of a meal bolus command, the process implemented by the AP application may consider a number of hours (e.g. 6 hours) as the post prandial period.
  • the artificial pancreas application may keep track of the dosages of insulin delivered during the post prandial time period by a drug delivery device (operable to automatically deliver insulin) or based on inputs from a user regarding dosages of insulin delivered to a user.
  • the artificial pancreas application may be operable to determine an error factor representing an amount of insulin over or under delivered during the post prandial period (165).
  • the artificial pancreas application may receive blood glucose measurements (labeled as CGM in Eq No. 2) during the post prandial period.
  • the artificial pancreas application may determine a difference between a received blood glucose measurement to the target blood glucose setting for that particular iteration. The differences may be summed during the post prandial period. The summed differences may then be divided by a correction factor that accounts for the user's ability to process delivered insulin.
  • the artificial pancreas application may be operable to determine a difference between the determined amount of insulin onboard and the error factor. This will determination provides an amount of insulin that the user was estimated to require to compensate for the ingestion of the meal.
  • the artificial pancreas application may be operable to calculate an updated insulin to carbohydrate ratio based on the determined difference and the approximate amount of carbohydrates ingested (168).
  • the calculated updated insulin i.e., IC new2 in Equation No. 2
  • the artificial pancreas application may use the calculated updated insulin in further calculations of dosages of insulin to be delivered by a drug delivery device or by a user.
  • the artificial pancreas application may be operable make a new calculation of a dosage, such as a basal dosage, a bolus dosage (for a next meal), or the like, based on the calculated updated insulin (i.e., ICnew2 in Equation No. 2).
  • the artificial pancreas application may be operable to modify delivery of insulin based on the updated insulin to carbohydrate ratio (i.e., IC new2 ).
  • the modified delivery of insulin may be a newly calculated amount of insulin to be delivered in a next dosage, a time of the next dosage, or both a modification of the amount of insulin to be delivered and a time of the delivery of a next dose of insulin.
  • the accuracy of the ICnew1 or ICnew2 as determined according to the examples of FIGs. 1A and 1B that utilize Equation Nos. 1 and 2 may be confirmed using the following rules.
  • the new IC ratio can be compared with a correction factor (CF) that is calculated based on the user's average glucose excursions divided by the user's average insulin delivery excursions beyond the basal value.
  • CF correction factor
  • the artificial pancreas application may be operable to confirm that the new IC ratio was accurately calculated and are within a specified tolerance, such as a range. Based on the determination that the calculation of the new IC ratio by the artificial pancreas application is within a predetermined tolerance of the estimated IC, the artificial pancreas application may continue modification of the delivery of insulin.
  • a specified tolerance such as a range
  • the artificial pancreas application may perform a further update of the IC ratio using additional blood glucose measurements received since the previous calculation of the new IC ratio, or the like.
  • FIG. 2 illustrates an example of a drug delivery system 200.
  • the drug delivery system 200 may be operable to implement an AP application that includes functionality to determine a bolus dosage, output an indication of the determined bolus dosage to actuate delivery of the bolus of insulin based on the indication of the determined bolus dosage.
  • the drug delivery system 200 may be an automated drug delivery system that may include a medical device (pump) 202, a sensor 204, and a management device (PDM) 206.
  • the system 200 in an example, may also include a smart accessory device 207, which may communicate with the other components of system 200 either via a wired or wireless communication link.
  • the medical device 202 may be attached to the body of a user, such as a patient or diabetic, and may deliver any therapeutic agent, including any drug or medicine, such as insulin or the like, to a user.
  • the medical device 202 may, for example, be a wearable device worn by the user.
  • the medical device 202 may be directly coupled to a user (e.g., directly attached to a body part and/or skin of the user via an adhesive or the like).
  • a surface of the medical device 202 may include an adhesive to facilitate attachment to a user.
  • the medical device 202 may, for example, include a number of components to facilitate automated delivery of a drug (also referred to as a therapeutic agent) to the user.
  • the medical device 202 may be operable to store the drug and to provide the drug to the user.
  • the medical device 202 is often referred to as a pump, or an insulin pump, in reference to the operation of expelling a drug from the reservoir 225 for delivery to the user. While the examples refer to the reservoir 225 storing insulin, the reservoir 225 may be operable to store other drugs or therapeutic agents, such as morphine or the like, suitable for automated delivery.
  • the medical device 202 may be an automated, wearable insulin delivery device.
  • the medical device 202 may include a reservoir 225 for storing the drug (such as insulin), a needle or cannula (not shown) for delivering the drug into the body of the user (which may be done subcutaneously, intraperitoneally, or intravenously), and a pump mechanism (mech.) 224, or other drive mechanism, for transferring the drug from the reservoir 225, through a needle or cannula (not shown), and into the user.
  • the pump mechanism 224 may be fluidly coupled to reservoir 225, and communicatively coupled to the processor 221.
  • the medical device 202 may also include a power source 228, such as a battery, a piezoelectric device, or the like, for supplying electrical power to the pump mechanism 224 and/or other components (such as the processor 221, memory 223, and the communication device 226) of the medical device 202.
  • a power source 228, such as a battery, a piezoelectric device, or the like for supplying electrical power to the pump mechanism 224 and/or other components (such as the processor 221, memory 223, and the communication device 226) of the medical device 202.
  • an electrical power supply for supplying electrical power may similarly be included in each of the sensor 204, the smart accessory device 207 and the management device (PDM) 206.
  • the blood glucose sensor 204 may be a device communicatively coupled to the processor 261 or 221 and may be operable to measure a blood glucose value at a predetermined time interval, such as every 5 minutes, or the like.
  • the blood glucose sensor 204 may provide a number of blood glucose measurement values to the AP applications operating on the respective devices.
  • the medical device 202 may provide insulin the stored in reservoir 225 to the user based on information (e.g., blood glucose measurement values) provided by the sensor 204 and/or the management device (PDM) 206.
  • the medical device 202 may contain analog and/or digital circuitry that may be implemented as a processor 221 (or controller) for controlling the delivery of the drug or therapeutic agent.
  • the circuitry used to implement the processor 221 may include discrete, specialized logic and/or components, an application-specific integrated circuit, a microcontroller or processor that executes software instructions, firmware, programming instructions or programming code (enabling, for example, the artificial pancreas application (AP App) 229 as well as the process examples of FIGs. 1 and 3 ) stored in memory 223, or any combination thereof.
  • the processor 221 may execute a control algorithm, such as an artificial pancreas application 229, and other programming code that may make the processor 221 operable to cause the pump to deliver doses of the drug or therapeutic agent to a user at predetermined intervals or as needed to bring blood glucose measurement values to a target blood glucose value.
  • the AP App 229 may include programming code that is operable upon execution by the processor 221 to provide the example processes for adjusting or modifying insulin-carbohydrate ratio and total daily insulin settings as described with reference to FIGs. 1A , 1B , 1C , 3 and 4 .
  • the size and/or timing of the doses may be programmed, for example, into an artificial pancreas application 229 by the user or by a third party (such as a health care provider, medical device manufacturer, or the like) using a wired or wireless link, such as 220, between the medical device 202 and a management device 206 or other device, such as a computing device at a healthcare provider facility.
  • the pump or medical device 202 is communicatively coupled to the processor 261 of the management device via the wireless link 220 or via a wireless link, such as 291 from smart accessory device 207 or 208 from the sensor 204.
  • the pump mechanism 224 of the medical device may be operable to receive an actuation signal from the processor 261, and in response to receiving the actuation signal, expel insulin from the reservoir 225 according to the set insulin bolus dosage.
  • the other devices in the system 200 may also be operable to perform various functions including controlling the medical device 202.
  • the management device 206 may include a communication device 264, a processor 261, and a management device memory 263.
  • the management device memory 263 may store an instance of the AP application 269 that includes programming code, that when executed by the processor 261 provides the process examples described with reference to the examples of FIGs. 1 and 3 .
  • the management device memory 263 may also store programming code for providing the process examples described with reference to the examples of FIGs. 1 and 3-7.
  • the smart accessory device 207 may be, for example, an Apple Watch ® , other wearable smart device, including eyeglasses, provided by other manufacturers, a global positioning system-enabled wearable, a wearable fitness device, smart clothing, or the like. Similar to the management device 206, the smart accessory device 207 may also be operable to perform various functions including controlling the medical device 202.
  • the smart accessory device 207 may include a communication device 274, a processor 271, and a memory 273.
  • the memory 273 may store an instance of the AP application 279 that includes programming code for providing the process examples described with reference to the examples of FIGs. 1 and 3-7.
  • the memory 273 may also as store programming code and be operable to store data related to the AP application 279.
  • the sensor 204 of system 200 may be a continuous glucose monitor (CGM) as described above, that may include a processor 241, a memory 243, a sensing or measuring device 244, and a communication device 246.
  • the memory 243 may store an instance of an AP application 249 as well as other programming code and be operable to store data related to the AP application 249.
  • the AP application 249 may also include programming code for providing the process examples described with reference to the examples of FIGs. 1 and 3 -7.
  • Instructions for determining the delivery of the drug or therapeutic agent (e.g., as a bolus dosage) to the user may originate locally by the medical device 202 or may originate remotely and be provided to the medical device 202.
  • programming instructions such as an instance of the artificial pancreas application 229, stored in the memory 223 that is coupled to the medical device 202 may be used to make determinations by the medical device 202.
  • the medical device 202 may be operable to communicate with the cloud-based services 211 via the communication device 226 and the communication link 288.
  • the remote instructions may be provided to the medical device 202 over a wired or wireless link by the management device (PDM) 206, which has a processor 261 that executes an instance of the artificial pancreas application 269, or the smart accessory device 207, which has a processor 271 that executes an instance of the artificial pancreas application 269 as well as other programming code for controlling various devices, such as the medical device 202, smart accessory device 207 and/or sensor 204.
  • the medical device 202 may execute any received instructions (originating internally or from the management device 206) for the delivery of the drug or therapeutic agent to the user. In this way, the delivery of the drug or therapeutic agent to a user may be automated.
  • the medical device 202 may communicate via a wireless link 220 with the management device 206.
  • the management device 206 may be an electronic device such as, for example, a smart phone, a tablet, a dedicated diabetes therapy management device, or the like.
  • the management device 206 may be a wearable wireless accessory device.
  • the wireless links 208, 220, 222, 291, 292 and 293 may be any type of wireless link provided by any known wireless standard.
  • the wireless links 208, 220, 222, 291, 292 and 293 may enable communications between the medical device 202, the management device 206 and sensor 204 based on, for example, Bluetooth ® , Wi-Fi ® , a near-field communication standard, a cellular standard, or any other wireless optical or radio-frequency protocol.
  • the sensor 204 may be a glucose sensor operable to measure blood glucose and output a blood glucose value or data that is representative of a blood glucose value.
  • the sensor 204 may be a glucose monitor or a continuous glucose monitor (CGM).
  • the sensor 204 may include a processor 241, a memory 243, a sensing/measuring device 244, and communication device 246.
  • the communication device 246 of sensor 204 may include one or more sensing elements, an electronic transmitter, receiver, and/or transceiver for communicating with the management device 206 over a wireless link 222 or with medical device 202 over the link 208.
  • the sensing/measuring device 244 may include one or more sensing elements, such as a glucose measurement, heart rate monitor, or the like.
  • the processor 241 may include discrete, specialized logic and/or components, an application-specific integrated circuit, a microcontroller or processor that executes software instructions, firmware, programming instructions stored in memory (such as memory 243), or any combination thereof.
  • the memory 243 may store an instance of an AP application 249 that is executable by the processor 241.
  • the sensor 204 is depicted as separate from the medical device 202, in various examples, the sensor 204 and medical device 202 may be incorporated into the same unit. That is, in various examples, the sensor 204 may be a part of the medical device 202 and contained within the same housing of the medical device 202 (e.g., the sensor 204 may be positioned within or embedded within the medical device 202).
  • Glucose monitoring data e.g., measured blood glucose values
  • determined by the sensor 204 may be provided to the medical device 202, smart accessory device 207 and/or the management device 206 and may be used to determine a bolus dosage of insulin for automated delivery of insulin by the medical device 202.
  • the sensor 204 may also be coupled to the user by, for example, adhesive or the like and may provide information or data on one or more medical conditions and/or physical attributes of the user. The information or data provided by the sensor 204 may be used to adjust drug delivery operations of the medical device 202.
  • the management device 206 may be a computing device operable to manage a personal diabetes treatment plan.
  • the management device 206 may be used to program or adjust operation of the medical device 202 and/or the sensor 204.
  • the management device 206 may be any portable electronic, computing device including, for example, a dedicated controller, such as processor 261, a smartphone, or a tablet.
  • the management device (PDM) 206 may include a processor 261, a management device management device memory 263, and a communication device 264.
  • the management device 206 may contain analog and/or digital circuitry that may be implemented as a processor 261 (or controller) for executing processes to manage a user's blood glucose levels and for controlling the delivery of the drug or therapeutic agent to the user.
  • the processor 261 may also be operable to execute programming code stored in the management device management device memory 263.
  • the management device management device memory 263 may be operable to store an artificial pancreas application 269 that may be executed by the processor 261.
  • the processor 261 may when executing the artificial pancreas application 269 may be operable to perform various functions, such as those described with respect to the examples in FIGs. 1 and 3 .
  • the communication device 264 may be a receiver, a transmitter, or a transceiver that operates according to one or more radio-frequency protocols.
  • the communication device 264 may include a cellular transceiver and a Bluetooth transceiver that enables the management device 206 to communicate with a data network via the cellular transceiver and with the sensor 204 and the medical device 202.
  • the respective transceivers of communication device 264 may be operable to transmit signals containing information useable by or generated by the AP application or the like.
  • the communication devices 226, 246 and 276 of respective medical device 202, sensor 204 and smart accessory device 207 may also be operable to transmit signals containing information useable by or generated by the AP application or the like.
  • the medical device 202 may communicate with the sensor 204 over a wireless link 208 and may communicate with the management device 206 over a wireless link 220.
  • the sensor 204 and the management device 206 may communicate over a wireless link 222.
  • the smart accessory device 207 when present, may communicate with the medical device 202, the sensor 204 and the management device 206 over wireless links 291, 292 and 293, respectively.
  • the wireless links 208, 220, 222, 291, 292 and 293 may be any type of wireless link operating using known wireless standards or proprietary standards.
  • the wireless links 208, 220, 222, 291, 292 and 293 may provide communication links based on Bluetooth ® , Wi-Fi, a near-field communication standard, a cellular standard, or any other wireless protocol via the respective communication devices 226, 246 and 264.
  • the medical device 202 and/or the management device 206 may include a user interface 227, 278 and 268, respectively, such as a keypad, a touchscreen display, levers, buttons, a microphone, a speaker, a display, or the like, that is operable to allow a user to enter information and allow the management device to output information for presentation to the user.
  • the drug delivery system 200 may be an insulin drug delivery system.
  • the medical device 202 may be the OmniPod ® (Insulet Corporation, Billerica, MA) insulin delivery device as described in U.S. Pat. No. 7,303,549 , U.S. Pat. No. 7,137,964 , or U.S. Pat. No. 6,740,059 , each of which is incorporated herein by reference in its entirety.
  • the drug delivery system 200 may implement the artificial pancreas (AP) algorithm (and/or provide AP functionality) to govern or control automated delivery of insulin to a user (e.g., to maintain euglycemia - a normal level of glucose in the blood).
  • the AP application may be implemented by the medical device 202 and/or the sensor 204.
  • the AP application may be used to determine the times and dosages of insulin delivery.
  • the AP application may determine the times and dosages for delivery based on information known about the user, such as the user's sex, age, weight, or height, and/or on information gathered about a physical attribute or condition of the user (e.g., from the sensor 204).
  • the AP application may determine an appropriate delivery of insulin based on glucose level monitoring of the user through the sensor 204.
  • the AP application may also allow the user to adjust insulin delivery.
  • the AP application may allow the user to issue (e.g., via an input) commands to the medical device 202, such as a command to deliver an insulin bolus.
  • different functions of the AP application may be distributed among two or more of the management device 206, the medical device (pump) 202 or the sensor 204.
  • the different functions of the AP application may be performed by one device, such the management device 206, the medical device (pump) 202 or the sensor 204.
  • the drug delivery system 200 may operate according to or may include features or functionalities of the drug delivery systems described in U.S. Patent Application No. 15/359,187, filed November 22, 2016 , which is incorporated herein by reference in its entirety.
  • the drug delivery system 200 or any component thereof, such as the medical device may be considered to provide AP functionality or to implement an AP application.
  • references to the AP application e.g., functionality, operations, or capabilities thereof
  • the drug delivery system 200 - for example, as an insulin delivery system implementing an AP application - may be considered to be a drug delivery system or an AP application-based delivery system that uses sensor inputs (e.g., data collected by the sensor 204).
  • one or more of the devices, 202, 204, 206 or 207 may be operable to communicate via a wireless communication link 288 with cloud-based services 211.
  • the cloud-based services 211 may utilize servers and data storage (not shown).
  • the communication link 288 may be a cellular link, a Wi-Fi link, a Bluetooth link, or a combination thereof, that is established between the respective devices 202, 204, 206 or 207 of system 200.
  • the data storage provided by the cloud-based services 211 may store anonymized data, such as user weight, blood glucose measurements, age, meal carbohydrate information, or the like.
  • the cloud-based services 211 may process the anonymized data from multiple users to provide generalized information related to the various parameters used by the AP application.
  • an age-based general target blood glucose value may be derived from the anonymized data, which may be helpful when a user first begins using a system such as 200.
  • the cloud-based services 211 may also provide processing services for the system 200, such as performing the process 100 in the example of FIG. 2 or additional processes, such as that described below with reference to FIG. 3 .
  • the device 202 includes a communication device 264, which as described above may be a receiver, a transmitter, or a transceiver that operates according to one or more radio-frequency protocols, such as Bluetooth, Wi-Fi, a near-field communication standard, a cellular standard, that may enable the respective device to communicate with the cloud-based services 211.
  • a communication device 264 which as described above may be a receiver, a transmitter, or a transceiver that operates according to one or more radio-frequency protocols, such as Bluetooth, Wi-Fi, a near-field communication standard, a cellular standard, that may enable the respective device to communicate with the cloud-based services 211.
  • radio-frequency protocols such as Bluetooth, Wi-Fi, a near-field communication standard, a cellular standard
  • outputs from the sensor 204 or the medical device (pump) 202 may be transmitted to the cloud-based services 211 for storage or processing via the transceivers of communication device 264.
  • medical device 202, management device 206 and sensor 204 may be
  • the respective receiver or transceiver of each respective device, 202, 206 or 207 may be operable to receive signals containing respective blood glucose measurement values of the number of blood glucose measurement values that may be transmitted by the sensor 204.
  • the respective processor of each respective device 202, 206 or 207 may be operable to store each of the respective blood glucose measurement values in a respective memory, such as 223, 263 or 273.
  • the respective blood glucose measurement values may be stored as data related to the artificial pancreas algorithm, such as 229, 249, 269 or 279.
  • the AP application operating on any of the management device 206, the smart accessory device 207, or sensor 204 may be operable to transmit, via a transceiver implemented by a respective communication device, 264, 274, 246, a control signal for receipt by a medical device.
  • the control signal may indicate an amount of insulin to be expelled by the medical device 202.
  • system 200 may be operable to implement the process examples of FIG. 1A-C .
  • system 200 may be operable to implement a process that accounts for periodic advanced TDI adaptivity using past glucose control performance as described with reference to FIG. 3 .
  • FIG. 3 illustrates a process example for determining periodic advanced TDI adaptivity using past glucose control performance.
  • a user's TDI may be adapted based on glucose control performance which enables a more accurate value of the parameter to be achieved.
  • the determination of the TDI parameter can be calculated by either taking the entire glucose control performance into account or taking individual point-wise blood glucose measurement values provided by a continuous glucose monitor (CGM).
  • CGM continuous glucose monitor
  • the difference between daily mean glucose and the user's desired control target can be related to the user's correction factor (CF) to calculate additional insulin that the user may need throughout the day.
  • CF correction factor
  • a CGM provides performs a blood glucose measurement in approximately 5 minute intervals).
  • the artificial pancreas application may calculate a point-wise excursion between the user's blood glucose measurements versus the user's target blood glucose setting. The point-wise excursion may be incorporated to generate an overall sum of additional insulin that the user may need at each cycle.
  • Prior implementations may make a total daily insulin (TDI) estimation by taking the sum of an insulin pump user's daily insulin deliveries across multiple days (i.e. one week) and taking the average of the sums as the estimate.
  • TDI estimates made in the manner of prior implementations may accidently omit dosages delivered manually (i.e., manual injections) or other under or over reporting of delivery of insulin.
  • an average of past insulin deliveries indicate the dosage that the user is comfortable with, but it does not necessarily indicate that the past insulin deliveries were well matched to the user's needs. For instance, if the user's average glucose concentration was very high, e.g. above the hyperglycemic threshold of 180 mg/dL, then the average insulin delivery during this period most likely does not represent the optimal insulin delivery value needed by the user.
  • TDI may be an input into the automatic insulin delivery algorithm utilized by the artificial pancreas application. Modification of total daily insulin (TDI) may be determined based on incorporation of daily mean blood glucose measurement values. In the example of FIG. 3 , the mean of the user's blood glucose measurements may be incorporated in addition to the user's new insulin delivery values to generate a new TDI value that more accurately reflects the user's insulin needs.
  • the process 300 may include a step of retrieving a prior TDI, the prior TDI may be the current TDI used by the artificial pancreas application to make insulin dosage calculations (310). In the example of Equation No. 3 below, the current TDI may be TDIold.
  • the retrieved TDI (i.e., TDI old ) may be multiplied by a first coefficient that indicates a confidence level of the TDI setting.
  • This first factor may be a prior TDI contribution term.
  • the artificial pancreas application may set the coefficient value to a higher value (e.g., closer to 1.0) to correspond with a higher level of confidence.
  • the consistency of the blood glucose measurement values may be used to determine coefficient values - more consistent blood glucose measurement values within a normal range may cause greater confidence while blood glucose measurement values within a normal range being less consistent may cause lower confidence. Based on the consistency of the blood glucose measurements, the artificial pancreas application may determine the value of the first confidence coefficient.
  • the retrieved total daily insulin may be multiplied by the first confidence coefficient (320).
  • the prior TDI contribution term may be (0.8* TDI old ).
  • the first confidence coefficient may be 0.8.
  • the value of the first confidence may have different values, such as 0.2, 0.5, 0.6 or the like, as determined by the artificial pancreas application.
  • the process 300 may determine the average excursion of the blood glucose measurements from blood glucose target settings as represented by the second factor in the example of Equation No. 3.
  • the artificial pancreas application may obtain after a predetermined period of time, such as 12 hours, 24 hours, 48 hours, or the like, the mean of the blood glucose measurement values collected during the predetermined period of time (i.e., (6)) (330).
  • the artificial pancreas application may further obtain the target blood glucose measurement settings for the determined period of time.
  • the mean target blood glucose measurement setting i.e., ( target )
  • This may be considered be a correction factor that is determined as a point-wise excursion between the user's glucose versus the user's target, calculated during each 5 minute interval.
  • a difference between the mean of the blood glucose measurement values and the blood glucose target settings may be determined by the artificial pancreas application.
  • the determined difference is the numerator of the second factor.
  • the artificial pancreas application may proceed to determining the denominator of the second factor.
  • the denominator may be a correction factor that may be determined utilizing different rules of thumb based on the type of insulin being used and a TDI setting.
  • a value of 1800 may be divided by the retrieved total daily insulin setting (i.e., TDI old ) to calculate the correction factor value.
  • a value of 1500 may be divided by the retrieved total daily insulin setting (i.e., TDI old ) to calculate the correction factor value.
  • the second factor may be a correction factor determined by dividing the difference in the numerator by the correction factor of the denominator to calculate the missing or excess insulin delivery throughout the day.
  • the correction factor can be incorporated in the equation to generate an overall sum of additional insulin that the user may need at each cycle.
  • a cycle being the time period that the new TDI is calculated. For example, a cycle may be 24 hours, 12 hours 8 hours or the like.
  • G may be the mean of the blood glucose measurement values collected during the predetermined period of time
  • target may be the mean of the blood glucose measurement target values during the predetermined period of time
  • I(t) is the insulin delivered at time t.
  • the coefficient of 8 represents 24 hours divided by different segments of 3 hours each, given the assumption that it will take a number of hours approximately equal to the duration of insulin action (DIA) for a user to reduce the mean blood glucose measurement to the target blood glucose setting.
  • the correction factor for example,1800/ TDI old
  • CF user's correction factor
  • other rules such as the 1500 rule, may be used.
  • the third term may be a delivered TDI term that is determined using data collected by the artificial pancreas application at 340. Since the artificial pancreas application controls how much insulin is delivered, the artificial pancreas application may store the amount of insulin delivered with each dose in a memory coupled to the processor executing the artificial pancreas application. For example, the artificial pancreas application may deliver insulin is a number of small doses over a period of time. In the example of Equation No. 3, the summation of the delivered insulin is over 288 doses of insulin. In this example, the insulin may be delivered every 5 minutes or 12 time an hour. Over a period of 24 hours, the artificial pancreas application send instructions for the delivery of 288 doses of insulin. In addition, this sum of delivered insulin may be multiplied by a second confidence factor that is the difference between 1.0 and the first confidence factor. In the example of Equation No. 3, the first confidence factor to 0.8, so the difference between 1.0 and 0.8 is 0.2.
  • a new TDI setting (i.e., TDI new3 ) may be determined by summing the prior TDI contribution term, the correction factor term and the delivered insulin term.
  • the artificial pancreas application may modify a next delivery of insulin (360). For example, a new insulin dosage may be determined, and the delivery of insulin may be actuated by the artificial pancreas application.
  • the first and second confidence factors may be parameterized so that some of the changes to the user's blood glucose measurements may occur more quickly.
  • the first confidence factor may be set to 0.5 in which case the second confidence factor may also be 0.5.
  • the adjustment to TDI may be segmented to avoid adjusting the TDI if the mean glucose blood glucose measurement is close to the target and to reduce vulnerability to noise, as shown in Equation No. 4 shown below:
  • I e ⁇ abs G ⁇ ⁇ target ⁇ > 40 G ⁇ ⁇ target ⁇ 1800 / TDI old abs G ⁇ ⁇ target ⁇ ⁇ 40 0
  • the threshold of 40 (mg/dL) that is compared to the excursion of the blood glucose measurements from the target blood glucose measurement setting is selected based on the correction factor.
  • the correction factor may be close to 40 for a typical user, the basis for the selection of 40 is that at times the excursions in blood glucose measurements may be due to noise or other extraneous inputs and the threshold 40 represents a reciprocal of the correction factor and is approximately equivalent to one unit of insulin. This is intended to avoid over compensating for excursions in the blood glucose measurements.
  • the TDI modification that produces TDI new4 may be based on a point-by-point residual insulin needs after an IOB is determined.
  • point-by-point excursions of the user's blood glucose measurements versus the user's blood glucose measurement target setting may be related to the user's correction factor to enable the artificial pancreas application to adjust the user's TDI dynamically.
  • the modification of TDI based on point-by-point residual insulin needs after an insulin onboard (IOB) is provided may be determined as shown in the example of equation no. 5 and FIG. 4 . This may be a periodic adjustment or modification of TDI.
  • the artificial pancreas application executed by the processor may, at 410, obtain a current TDI setting (e.g., TDI old ) either from a memory or user input.
  • the artificial pancreas application may determine a first factor in a new TDI function of Equation No. 5 using the current TDI setting by multiplying the current TDI by a first coefficient, where the first coefficient indicates a confidence level of the TDI setting. This first factor may be a prior TDI contribution term.
  • the artificial pancreas application may set the coefficient valuer a higher to correspond with a higher level of confidence.
  • the artificial pancreas application may determine a second factor in the new TDI function (Equation No. 5) by retrieving amounts of insulin delivered over a period of time, such as every 5 minutes over 24 hours or 288 delivered doses, summing the amounts of insulin delivered, and multiplying the sum by a second confidence factor.
  • a third factor may be determined, at 440, that accounts for the excursions of IOB that occur in 3 hour increments and since there are 12 blood glucose measurements received every hour (e.g., 3 time 12 equals 36).
  • the third factor accounts for the deviation of blood glucose measurements from target blood glucose measurement settings (e.g., G(t)) - target (t)) which is converted to an amount of insulin by dividing that difference using the 1800 rule (which may be a 1500 rule or the like depending upon the type of insulin being used (e.g., fast acting versus regular acting).
  • the artificial pancreas application may sum the first factor, the second factor and the third factor to arrive at a new TDI (i.e., TDI new5 ) at 450.
  • the new TDI i.e., TDI new2
  • the new TDI may be used by the artificial pancreas application in the calculation of a new dosage of insulin to be provided by a drug delivery device to the user.
  • the artificial pancreas application may generate control commands that are sent to the drug delivery device instructing the drug delivery device to deliver a dose of insulin according the control command (460).
  • the dose of insulin may be delivered by the drug delivery device according to the control command.
  • the factor 8 represents the maximum duration of insulin action, to apply a conservative estimate of TDI modification assuming that an increase in glucose can be covered by 8 hours of insulin delivery. This value can be adjusted as a tuning parameter to different values, such as 2, 3, 4, 5, 6, 7, or 8.
  • the first term represents the duration of time of new data available ("weighing of the previous TDI estimate")
  • the second term represents adjustment of the current TDI estimate based on deviation in average glucose during this new data versus the target, modified by duration in insulin action
  • the third term represents the actual insulin delivery that occurred during this period of new data.
  • the techniques described herein for providing a determination of a new insulin-to-carbohydrate ratio and a new total daily insulin factor for a drug delivery system may be implemented in hardware, software, or any combination thereof.
  • the system 200 or any component thereof may be implemented in hardware, software, or any combination thereof.
  • Software related implementations of the techniques described herein may include, but are not limited to, firmware, application specific software, or any other type of computer readable instructions that may be executed by one or more processors.
  • Hardware related implementations of the techniques described herein may include, but are not limited to, integrated circuits (ICs), application specific ICs (ASICs), field programmable arrays (FPGAs), and/or programmable logic devices (PLDs).
  • ICs integrated circuits
  • ASICs application specific ICs
  • FPGAs field programmable arrays
  • PLDs programmable logic devices
  • the techniques described herein, and/or any system or constituent component described herein may be implemented with a processor executing computer readable instructions stored on
  • Some embodiments of the disclosed device may be implemented, for example, using a storage medium, a computer-readable medium, or an article of manufacture which may store an instruction or a set of instructions that, if executed by a machine (i.e., processor or microcontroller), may cause the machine to perform a method and/or operation in accordance with embodiments of the disclosure.
  • a machine i.e., processor or microcontroller
  • Such a machine may include, for example, any suitable processing platform, computing platform, computing device, processing device, computing system, processing system, computer, processor, or the like, and may be implemented using any suitable combination of hardware and/or software.
  • the computer-readable medium or article may include, for example, any suitable type of memory unit, memory, memory article, memory medium, storage device, storage article, storage medium and/or storage unit, for example, memory (including non-transitory memory), removable or non-removable media, erasable or non-erasable media, writeable or re-writeable media, digital or analog media, hard disk, floppy disk, Compact Disk Read Only Memory (CD-ROM), Compact Disk Recordable (CD-R), Compact Disk Rewriteable (CD-RW), optical disk, magnetic media, magneto-optical media, removable memory cards or disks, various types of Digital Versatile Disk (DVD), a tape, a cassette, or the like.
  • memory including non-transitory memory
  • removable or non-removable media erasable or non-erasable media, writeable or re-writeable media, digital or analog media
  • hard disk floppy disk
  • CD-ROM Compact Disk Read Only Memory
  • CD-R Compact Disk Recordable
  • the instructions may include any suitable type of code, such as source code, compiled code, interpreted code, executable code, static code, dynamic code, encrypted code, programming code, and the like, implemented using any suitable high-level, low-level, object-oriented, visual, compiled and/or interpreted programming language.
  • the non-transitory computer readable medium embodied programming code may cause a processor when executing the programming code to perform functions, such as those described herein.
  • Storage type media include any or all of the tangible memory of the computers, processors or the like, or associated modules thereof, such as various semiconductor memories, tape drives, disk drives and the like, which may provide non-transitory storage at any time for the software programming.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • General Business, Economics & Management (AREA)
  • Business, Economics & Management (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Data Mining & Analysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Surgery (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Databases & Information Systems (AREA)
  • Nutrition Science (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Ecology (AREA)
  • Dermatology (AREA)
  • Signal Processing (AREA)
  • Optics & Photonics (AREA)
  • Artificial Intelligence (AREA)

Claims (4)

  1. Support non transitoire lisible par ordinateur pourvu d'un code de programmation exécutable par un processeur, le processeur, lors de l'exécution du code de programmation, étant utilisable pour assurer des fonctions, y compris des fonctions pour :
    récupérer (110) un rapport insuline/glucides antérieur (ICold) ;
    surveiller (120) un nombre de mesures de glycémie en dessous d'un seuil d'hypoglycémie ;
    déterminer (130) un facteur de correction de rapport insuline/glucides d'hypoglycémie sur la base du nombre surveillé de mesures de glycémie en dessous du seuil d'hypoglycémie ;
    surveiller (140) un nombre de mesures de glycémie qui dépassent un seuil d'hyperglycémie ;
    déterminer (150) un facteur de correction de rapport insuline/glucides d'hyperglycémie sur la base du nombre surveillé de mesures de glycémie qui dépassent un seuil hypoglycémique ;
    surveiller (160) un nombre de fois qu'une application de pancréas artificiel a été dans un état de suspension de délivrance d'insuline ;
    déterminer (170) un facteur de correction de rapport insuline/glucides de suspension sur la base du nombre de fois que l'application de pancréas artificiel a été dans l'état de suspension de délivrance d'insuline ;
    surveiller (180) un nombre de doses d'insuline délivrées pour lesquelles une quantité d'insuline dans la dose délivrée dépassait un réglage de dosage d'insuline de base au moment où la dose d'insuline a été délivrée ;
    déterminer (185) un facteur de correction de rapport insuline/glucides de dépassement de base sur la base du nombre surveillé de doses d'insuline délivrées pour lesquelles la quantité d'insuline dans la dose délivrée dépassait un réglage de dosage d'insuline de base ;
    calculer (190) un nouveau rapport insuline/glucides (Icnew ; ICnew1 ; ICnew2) sur la base du rapport insuline/glucides antérieur (ICold), du facteur de correction de rapport insuline/glucides d'hypoglycémie déterminé, du facteur de correction de rapport insuline/glucides d'hyperglycémie déterminé, du facteur de correction de rapport insuline/glucides de suspension déterminé, et du facteur de correction de rapport insuline/glucides de dépassement de base déterminé ; et
    actionner (195) la délivrance d'une dose d'insuline suivante sur la base d'un dosage d'insuline calculé au moyen du nouveau rapport insuline/glucides calculé (Icnew ; ICnew1 ; ICnew2).
  2. Dispositif, comprenant :
    un processeur (221) ;
    une mémoire (223) stockant un code de programmation, une application de pancréas artificiel, et utilisable pour stocker des données associées à l'application de pancréas artificiel (229), le code de programmation et l'application de pancréas artificiel étant exécutables par le processeur ; et
    un émetteur-récepteur utilisable pour recevoir et émettre des signaux contenant des informations utilisables ou générées par l'application de pancréas artificiel ;
    dans lequel le processeur (221), lors de l'exécution de l'application de pancréas artificiel, est utilisable pour contrôler la délivrance d'insuline, et pour assurer des fonctions, y compris des fonctions pour :
    - récupérer (110) un rapport glucides/insuline antérieur (ICold) ;
    - surveiller (120) un nombre de mesures de glycémie en dessous d'un seuil d'hypoglycémie ;
    - déterminer (130) un facteur de correction de rapport insuline/glucides d'hypoglycémie sur la base du nombre surveillé de mesures de glycémie en dessous du seuil d'hypoglycémie ;
    - surveiller (140) un nombre de mesures de glycémie qui dépassent un seuil d'hyperglycémie ;
    - déterminer (150) un facteur de correction de rapport insuline/glucides d'hyperglycémie sur la base du nombre surveillé de mesures de glycémie qui dépassent un seuil hypoglycémique ;
    - surveiller (160) un nombre de fois qu'une application de pancréas artificiel a été dans un état de suspension de délivrance d'insuline ;
    - déterminer (170) un facteur de correction de rapport insuline/glucides de suspension sur la base du nombre de fois que l'application de pancréas artificiel a été dans l'état de suspension de délivrance d'insuline ;
    - surveiller (180) un nombre de doses d'insuline délivrées pour lesquelles une quantité d'insuline dans la dose délivrée dépassait un réglage de dosage d'insuline de base au moment où la dose d'insuline a été délivrée ;
    - déterminer (185) un facteur de correction de rapport insuline/glucides de dépassement de base sur la base du nombre surveillé de doses d'insuline délivrées pour lesquelles la quantité d'insuline dans la dose délivrée dépassait un réglage de dosage d'insuline de base ;
    - calculer (190) un nouveau rapport insuline/glucides (Icnew ; ICnew1 ; ICnew2) sur la base du rapport insuline/glucides antérieur (ICold), du facteur de correction de rapport insuline/glucides d'hypoglycémie déterminé, du facteur de correction de rapport insuline/glucides d'hyperglycémie déterminé, du facteur de correction de rapport insuline/glucides de suspension déterminé, et du facteur de correction de rapport insuline/glucides de dépassement de base déterminé ; et
    - actionner (195) la délivrance d'une dose d'insuline suivante sur la base d'un dosage d'insuline calculé au moyen du nouveau rapport insuline/glucides calculé (Icnew ; ICnew1 ; ICnew2).
  3. Dispositif selon la revendication 2, comprenant en outre un capteur de glycémie (204) couplé de façon communicante au processeur (221), utilisable pour mesurer une valeur de glycémie à un intervalle de temps prédéterminé et pour fournir la valeur de glycémie mesurée au processeur et à l'application de pancréas artificiel.
  4. Dispositif selon la revendication 2, comprenant en outre un réservoir (225) servant à stocker un médicament, une aiguille ou canule servant à délivrer le médicament dans le corps d'un utilisateur, et un mécanisme de pompage (224) servant à transférer le médicament depuis le réservoir (225) à travers l'aiguille ou la canule.
EP20830426.1A 2019-12-06 2020-12-04 Techniques et dispositifs de fourniture d'adaptabilité et de personnalisation dans le traitement du diabète Active EP4069082B1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP24159863.0A EP4354455B1 (fr) 2019-12-06 2020-12-04 Techniques et dispositifs fournissant une adaptivité et une personnalisation dans le traitement du diabète
EP25209420.6A EP4657456A3 (fr) 2019-12-06 2020-12-04 Techniques et dispositifs fournissant une adaptivité et une personnalisation dans le traitement du diabète

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962944792P 2019-12-06 2019-12-06
PCT/US2020/063326 WO2021113647A1 (fr) 2019-12-06 2020-12-04 Techniques et dispositifs de fourniture d'adaptabilité et de personnalisation dans le traitement du diabète

Related Child Applications (3)

Application Number Title Priority Date Filing Date
EP25209420.6A Division EP4657456A3 (fr) 2019-12-06 2020-12-04 Techniques et dispositifs fournissant une adaptivité et une personnalisation dans le traitement du diabète
EP24159863.0A Division EP4354455B1 (fr) 2019-12-06 2020-12-04 Techniques et dispositifs fournissant une adaptivité et une personnalisation dans le traitement du diabète
EP24159863.0A Division-Into EP4354455B1 (fr) 2019-12-06 2020-12-04 Techniques et dispositifs fournissant une adaptivité et une personnalisation dans le traitement du diabète

Publications (2)

Publication Number Publication Date
EP4069082A1 EP4069082A1 (fr) 2022-10-12
EP4069082B1 true EP4069082B1 (fr) 2024-06-05

Family

ID=74104189

Family Applications (3)

Application Number Title Priority Date Filing Date
EP25209420.6A Pending EP4657456A3 (fr) 2019-12-06 2020-12-04 Techniques et dispositifs fournissant une adaptivité et une personnalisation dans le traitement du diabète
EP24159863.0A Active EP4354455B1 (fr) 2019-12-06 2020-12-04 Techniques et dispositifs fournissant une adaptivité et une personnalisation dans le traitement du diabète
EP20830426.1A Active EP4069082B1 (fr) 2019-12-06 2020-12-04 Techniques et dispositifs de fourniture d'adaptabilité et de personnalisation dans le traitement du diabète

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EP25209420.6A Pending EP4657456A3 (fr) 2019-12-06 2020-12-04 Techniques et dispositifs fournissant une adaptivité et une personnalisation dans le traitement du diabète
EP24159863.0A Active EP4354455B1 (fr) 2019-12-06 2020-12-04 Techniques et dispositifs fournissant une adaptivité et une personnalisation dans le traitement du diabète

Country Status (3)

Country Link
US (2) US11957875B2 (fr)
EP (3) EP4657456A3 (fr)
WO (1) WO2021113647A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2586788A (en) * 2019-08-30 2021-03-10 Univ Warwick Electrocardiogram-based blood glucose level monitoring
EP4141879B1 (fr) * 2021-08-24 2026-04-29 Insulet Corporation Réglage du rapport insuline/glucide, facteur de correction, dosage d'insuline et synchronisation d'administration d'insuline à l'aide d'un dispositif d'administration de médicaments
WO2023172637A1 (fr) * 2022-03-09 2023-09-14 Insulet Corporation Valeur de la partie basale adaptative dans un dispositif d'administration de médicaments automatisé sur la base de l'historique d'administration de médicaments pour un utilisateur
US20240066213A1 (en) * 2022-08-24 2024-02-29 Insulet Corporation Techniques to increase rate of adaptivity for total daily insulin

Family Cites Families (582)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US303013A (en) 1884-08-05 Pen-holder
US5338157B1 (en) 1992-09-09 1999-11-02 Sims Deltec Inc Systems and methods for communicating with ambulat
US5935099A (en) 1992-09-09 1999-08-10 Sims Deltec, Inc. Drug pump systems and methods
US2797149A (en) 1953-01-08 1957-06-25 Technicon International Ltd Methods of and apparatus for analyzing liquids containing crystalloid and non-crystalloid constituents
US3631847A (en) 1966-03-04 1972-01-04 James C Hobbs Method and apparatus for injecting fluid into the vascular system
US3634039A (en) 1969-12-22 1972-01-11 Thomas L Brondy Blood testing machine
US3841328A (en) 1972-08-04 1974-10-15 J Jensen Airplane hijacking injector
US3812843A (en) 1973-03-12 1974-05-28 Lear Siegler Inc Method and apparatus for injecting contrast media into the vascular system
US4146029A (en) 1974-04-23 1979-03-27 Ellinwood Jr Everett H Self-powered implanted programmable medication system and method
US3963380A (en) 1975-01-06 1976-06-15 Thomas Jr Lyell J Micro pump powered by piezoelectric disk benders
US4245634A (en) 1975-01-22 1981-01-20 Hospital For Sick Children Artificial beta cell
CA1040271A (fr) 1975-01-22 1978-10-10 Anthony M. Albisser Cellule beta artificielle
US4055175A (en) 1976-05-07 1977-10-25 Miles Laboratories, Inc. Blood glucose control apparatus
US4151845A (en) 1977-11-25 1979-05-01 Miles Laboratories, Inc. Blood glucose control apparatus
US4559037A (en) 1977-12-28 1985-12-17 Siemens Aktiengesellschaft Device for the pre-programmable infusion of liquids
US4373527B1 (en) 1979-04-27 1995-06-27 Univ Johns Hopkins Implantable programmable medication infusion system
DE3023211A1 (de) 1979-06-28 1981-01-22 Ti Fords Ltd Verfahren und vorrichtung zur ermittlung einer waesserigen fluessigkeit in flaschen und behaeltern
US4403984A (en) 1979-12-28 1983-09-13 Biotek, Inc. System for demand-based adminstration of insulin
AU546785B2 (en) 1980-07-23 1985-09-19 Commonwealth Of Australia, The Open-loop controlled infusion of diabetics
US4559033A (en) 1980-10-27 1985-12-17 University Of Utah Research Foundation Apparatus and methods for minimizing peritoneal injection catheter obstruction
JPS57211361A (en) 1981-06-23 1982-12-25 Terumo Corp Liquid injecting apparatus
IT1142930B (it) 1981-11-04 1986-10-15 Luigi Bernardi Apparecchio portatile che infonde insulina sulla base dei rilevamenti glicemici
US4529401A (en) 1982-01-11 1985-07-16 Cardiac Pacemakers, Inc. Ambulatory infusion pump having programmable parameters
US4464170A (en) 1982-09-29 1984-08-07 Miles Laboratories, Inc. Blood glucose control apparatus and method
US4526568A (en) 1982-09-29 1985-07-02 Miles Laboratories, Inc. Diagnostic method and apparatus for clamping blood glucose concentration
US4624661A (en) 1982-11-16 1986-11-25 Surgidev Corp. Drug dispensing system
IT1170375B (it) 1983-04-19 1987-06-03 Giuseppe Bombardieri Apparecchio che infonde insulina o glucosio nel soggetto diabetico sulla base di determinazioni di concentrazioni di glucosio ottenute senza bisogno di prelievi del sangue del paziente
US4573968A (en) 1983-08-16 1986-03-04 Ivac Corporation Infusion and blood chemistry monitoring system
US4781693A (en) 1983-09-02 1988-11-01 Minntech Corporation Insulin dispenser for peritoneal cavity
US4743243A (en) 1984-01-03 1988-05-10 Vaillancourt Vincent L Needle with vent filter assembly
US4685903A (en) 1984-01-06 1987-08-11 Pacesetter Infusion, Ltd. External infusion pump apparatus
AU4409285A (en) 1984-06-29 1986-01-24 Hemascience Laboratories Inc. Blood extraction and reinfusion flow control system and method
US4755173A (en) 1986-02-25 1988-07-05 Pacesetter Infusion, Ltd. Soft cannula subcutaneous injection set
US5349852A (en) 1986-03-04 1994-09-27 Deka Products Limited Partnership Pump controller using acoustic spectral analysis
US4778451A (en) 1986-03-04 1988-10-18 Kamen Dean L Flow control system using boyle's law
AT384737B (de) 1986-04-04 1987-12-28 Thoma Dipl Ing Dr Techn Herwig Vorrichtung zur stroemungskonstanten abgabe fluessiger arzneimittel
US4731726A (en) 1986-05-19 1988-03-15 Healthware Corporation Patient-operated glucose monitor and diabetes management system
US4981140A (en) 1986-09-12 1991-01-01 Philip Wyatt Method and apparatus for arterial and venous blood sampling
US4886499A (en) 1986-12-18 1989-12-12 Hoffmann-La Roche Inc. Portable injection appliance
US4976720A (en) 1987-01-06 1990-12-11 Advanced Cardiovascular Systems, Inc. Vascular catheters
AT391998B (de) 1987-02-02 1990-12-27 Falko Dr Skrabal Vorrichtung zur bestimmung der konzentration zumindest einer medizinischen substanz in lebenden organismen
GB8710610D0 (en) 1987-05-05 1987-06-10 British Res Agricult Eng Rotor assemblies
US4940527A (en) 1987-06-01 1990-07-10 Abbott Laboratories Two-part test cartridge for centrifuge
US4925444A (en) 1987-08-07 1990-05-15 Baxter Travenol Laboratories, Inc. Closed multi-fluid delivery system and method
US5207642A (en) 1987-08-07 1993-05-04 Baxter International Inc. Closed multi-fluid delivery system and method
US4919596A (en) 1987-12-04 1990-04-24 Pacesetter Infusion, Ltd. Fluid delivery control and monitoring apparatus for a medication infusion system
US4994047A (en) 1988-05-06 1991-02-19 Menlo Care, Inc. Multi-layer cannula structure
JP2755654B2 (ja) 1988-07-07 1998-05-20 住友ベークライト株式会社 ブドウ糖濃度応答インスリン放出装置
US4854170A (en) 1988-10-12 1989-08-08 Separation Technology, Inc. Apparatus and method for using ultrasound to determine hematocrit
US5153827A (en) 1989-01-30 1992-10-06 Omni-Flow, Inc. An infusion management and pumping system having an alarm handling system
US6262798B1 (en) 1992-09-29 2001-07-17 Board Of Regents, The University Of Texas System Method and apparatus for direct spectrophotometric measurements in unaltered whole blood
IE62767B1 (en) 1989-03-17 1995-02-22 Baxter Int Pre-slit injection site and tapered cannula
CA1328359C (fr) 1989-03-27 1994-04-12 Michael D. Mintz Appareil et methode pour le prelevement et l'administration de liquides, surtout pour le prelevement de liquides organiques
US5134079A (en) 1989-03-27 1992-07-28 International Technidyne Corp. Fluid sample collection and delivery system and methods particularly adapted for body fluid sampling
US5102406A (en) 1989-06-02 1992-04-07 Arnold Victor A Device and method for avoiding contamination of multi-dose medicament vials
US5716343A (en) 1989-06-16 1998-02-10 Science Incorporated Fluid delivery apparatus
US4975581A (en) 1989-06-21 1990-12-04 University Of New Mexico Method of and apparatus for determining the similarity of a biological analyte from a model constructed from known biological fluids
US5007286A (en) 1989-08-03 1991-04-16 Malcolm Robert G Solid-state transducer based dynamic fluid flow sensing system
US5109850A (en) 1990-02-09 1992-05-05 Massachusetts Institute Of Technology Automatic blood monitoring for medication delivery method and apparatus
JPH0451966A (ja) 1990-06-19 1992-02-20 Toichi Ishikawa 薬液連続注入器
US5125415A (en) 1990-06-19 1992-06-30 Smiths Industries Medical Systems, Inc. Syringe tip cap with self-sealing filter
US5176662A (en) 1990-08-23 1993-01-05 Minimed Technologies, Ltd. Subcutaneous injection set with improved cannula mounting arrangement
US5165406A (en) 1990-09-13 1992-11-24 Via Medical Corporation Electrochemical sensor apparatus and method
US5468727A (en) 1990-12-13 1995-11-21 Board Of Regents, The University Of Texas System Methods of normalizing metabolic parameters in diabetics
TW279133B (fr) 1990-12-13 1996-06-21 Elan Med Tech
US5061424A (en) 1991-01-22 1991-10-29 Becton, Dickinson And Company Method for applying a lubricious coating to an article
US5273517A (en) 1991-07-09 1993-12-28 Haemonetics Corporation Blood processing method and apparatus with disposable cassette
JPH05209826A (ja) 1991-10-04 1993-08-20 Perkin Elmer Corp:The スペクトル比較方法および装置
US5244463A (en) 1991-12-06 1993-09-14 Block Medical, Inc. Programmable infusion pump
DE4141944C2 (de) 1991-12-19 1995-06-08 Hansa Metallwerke Ag Einrichtung zur berührungslosen Steuerung einer Sanitärarmatur
EP0549341A1 (fr) 1991-12-24 1993-06-30 W.R. Grace & Co.-Conn. Echantillonneur du plasma à fibres creuses
US5421812A (en) 1992-03-04 1995-06-06 Cobe Laboratories, Inc. Method and apparatus for controlling concentrations in tubing system
US5377674A (en) 1992-05-08 1995-01-03 Kuestner; J. Todd Method for non-invasive and in-vitro hemoglobin concentration measurement
US5385539A (en) 1992-06-30 1995-01-31 Advanced Haemotechnologies Apparatus for monitoring hematocrit levels of blood
US5342298A (en) 1992-07-31 1994-08-30 Advanced Cardiovascular Systems, Inc. Automated fluid pressure control system
US5330634A (en) 1992-08-28 1994-07-19 Via Medical Corporation Calibration solutions useful for analyses of biological fluids and methods employing same
US5232439A (en) 1992-11-02 1993-08-03 Infusion Technologies Corporation Method for pumping fluid from a flexible, variable geometry reservoir
US5956501A (en) 1997-01-10 1999-09-21 Health Hero Network, Inc. Disease simulation system and method
DE4336336A1 (de) 1992-11-23 1994-05-26 Lang Volker Kasetteninfusionssystem
US5299571A (en) 1993-01-22 1994-04-05 Eli Lilly And Company Apparatus and method for implantation of sensors
US5257980A (en) 1993-04-05 1993-11-02 Minimed Technologies, Ltd. Subcutaneous injection set with crimp-free soft cannula
DE69430152T2 (de) 1993-06-25 2002-10-31 Edward W. Stark Verfahren und Vorrichtung zum Messen von Glukoseverwandten Substanzen
DK88893D0 (da) 1993-07-30 1993-07-30 Radiometer As A method and an apparatus for determining the content of a constituent of blood of an individual
US5389078A (en) 1993-10-06 1995-02-14 Sims Deltec, Inc. Programmable infusion pump for administering medication to patients
US5582184A (en) 1993-10-13 1996-12-10 Integ Incorporated Interstitial fluid collection and constituent measurement
US5885211A (en) 1993-11-15 1999-03-23 Spectrix, Inc. Microporation of human skin for monitoring the concentration of an analyte
US5458140A (en) 1993-11-15 1995-10-17 Non-Invasive Monitoring Company (Nimco) Enhancement of transdermal monitoring applications with ultrasound and chemical enhancers
US5997501A (en) 1993-11-18 1999-12-07 Elan Corporation, Plc Intradermal drug delivery device
US5411889A (en) 1994-02-14 1995-05-02 Nalco Chemical Company Regulating water treatment agent dosage based on operational system stresses
EP0672427A1 (fr) 1994-03-17 1995-09-20 Siemens-Elema AB Dispositif de perfusion de médicament
US5569186A (en) 1994-04-25 1996-10-29 Minimed Inc. Closed loop infusion pump system with removable glucose sensor
DE4415896A1 (de) 1994-05-05 1995-11-09 Boehringer Mannheim Gmbh Analysesystem zur Überwachung der Konzentration eines Analyten im Blut eines Patienten
US5685859A (en) 1994-06-02 1997-11-11 Nikomed Aps Device for fixating a drainage tube and a drainage tube assembly
US5700695A (en) 1994-06-30 1997-12-23 Zia Yassinzadeh Sample collection and manipulation method
US5505709A (en) 1994-09-15 1996-04-09 Minimed, Inc., A Delaware Corporation Mated infusion pump and syringe
CA2159052C (fr) 1994-10-28 2007-03-06 Rainer Alex Dispositif d'injection
IE72524B1 (en) 1994-11-04 1997-04-23 Elan Med Tech Analyte-controlled liquid delivery device and analyte monitor
US5685844A (en) 1995-01-06 1997-11-11 Abbott Laboratories Medicinal fluid pump having multiple stored protocols
DE19500529C5 (de) 1995-01-11 2007-11-22 Dräger Medical AG & Co. KG Bedieneinheit für ein Beatmungsgerät
US5697899A (en) 1995-02-07 1997-12-16 Gensia Feedback controlled drug delivery system
EP0831946A4 (fr) 1995-02-07 1999-09-22 Gensia Inc Systeme d'administration des medicaments a retrocontrole
US5741228A (en) 1995-02-17 1998-04-21 Strato/Infusaid Implantable access device
US5665065A (en) 1995-05-26 1997-09-09 Minimed Inc. Medication infusion device with blood glucose data input
US5584813A (en) 1995-06-07 1996-12-17 Minimed Inc. Subcutaneous injection set
US5655530A (en) 1995-08-09 1997-08-12 Rio Grande Medical Technologies, Inc. Method for non-invasive blood analyte measurement with improved optical interface
US6240306B1 (en) 1995-08-09 2001-05-29 Rio Grande Medical Technologies, Inc. Method and apparatus for non-invasive blood analyte measurement with fluid compartment equilibration
US7016713B2 (en) 1995-08-09 2006-03-21 Inlight Solutions, Inc. Non-invasive determination of direction and rate of change of an analyte
US5879310A (en) 1995-09-08 1999-03-09 Integ, Inc. Body fluid sampler
US5693018A (en) 1995-10-11 1997-12-02 Science Incorporated Subdermal delivery device
US6072180A (en) 1995-10-17 2000-06-06 Optiscan Biomedical Corporation Non-invasive infrared absorption spectrometer for the generation and capture of thermal gradient spectra from living tissue
US6058934A (en) 1995-11-02 2000-05-09 Chiron Diagnostics Corporation Planar hematocrit sensor incorporating a seven-electrode conductivity measurement cell
US5800405A (en) 1995-12-01 1998-09-01 I-Flow Corporation Syringe actuation device
ATE396644T1 (de) 1995-12-19 2008-06-15 Abbott Lab Vorrichtung zum detektieren eines analyten und zur verabreichung einer therapeutischen substanz
US6040578A (en) 1996-02-02 2000-03-21 Instrumentation Metrics, Inc. Method and apparatus for multi-spectral analysis of organic blood analytes in noninvasive infrared spectroscopy
FI118509B (fi) 1996-02-12 2007-12-14 Nokia Oyj Menetelmä ja laitteisto potilaan veren glukoosipitoisuuden ennustamiseksi
US5703364A (en) 1996-02-15 1997-12-30 Futrex, Inc. Method and apparatus for near-infrared quantitative analysis
US5801057A (en) 1996-03-22 1998-09-01 Smart; Wilson H. Microsampling device and method of construction
US5865806A (en) 1996-04-04 1999-02-02 Becton Dickinson And Company One step catheter advancement automatic needle retraction system
SE9602298D0 (sv) 1996-06-11 1996-06-11 Siemens Elema Ab Arrangement for analysing body fluids
CA2259437C (fr) 1996-07-03 2006-12-05 Altea Technologies, Inc. Microporation mecanique multiple de la peau ou de la muqueuse
CA2259254C (fr) 1996-07-08 2008-02-19 Animas Corporation Capteur implantable et systeme de mesure et de controle in vivo de taux de constituants de fluides
US5758643A (en) 1996-07-29 1998-06-02 Via Medical Corporation Method and apparatus for monitoring blood chemistry
US5755682A (en) 1996-08-13 1998-05-26 Heartstent Corporation Method and apparatus for performing coronary artery bypass surgery
US5804048A (en) 1996-08-15 1998-09-08 Via Medical Corporation Electrode assembly for assaying glucose
US5932175A (en) 1996-09-25 1999-08-03 Via Medical Corporation Sensor apparatus for use in measuring a parameter of a fluid sample
US5714123A (en) 1996-09-30 1998-02-03 Lifescan, Inc. Protective shield for a blood glucose strip
JP3970331B2 (ja) 1996-11-22 2007-09-05 セラコス・インコーポレイテッド 流体の移動を弁操作、ポンプ処理および制御するための一体型カセット
US6071251A (en) 1996-12-06 2000-06-06 Abbott Laboratories Method and apparatus for obtaining blood for diagnostic tests
US5947911A (en) 1997-01-09 1999-09-07 Via Medical Corporation Method and apparatus for reducing purge volume in a blood chemistry monitoring system
JP3121356B2 (ja) 1997-01-17 2000-12-25 ビア メディカル コーポレイション 診断試験で使用されるセンサーの較正方法
US5851197A (en) 1997-02-05 1998-12-22 Minimed Inc. Injector for a subcutaneous infusion set
JP3394262B2 (ja) 1997-02-06 2003-04-07 セラセンス、インク． 小体積インビトロ被検体センサー
US6979309B2 (en) 1997-02-14 2005-12-27 Nxstage Medical Inc. Systems and methods for performing blood processing and/or fluid exchange procedures
WO1998037801A1 (fr) 1997-02-27 1998-09-03 Minnesota Mining And Manufacturing Company Cassette pour mesurer les parametres sanguins
US6741877B1 (en) 1997-03-04 2004-05-25 Dexcom, Inc. Device and method for determining analyte levels
US6161028A (en) 1999-03-10 2000-12-12 Optiscan Biomedical Corporation Method for determining analyte concentration using periodic temperature modulation and phase detection
US6270455B1 (en) 1997-03-28 2001-08-07 Health Hero Network, Inc. Networked system for interactive communications and remote monitoring of drug delivery
US5871470A (en) 1997-04-18 1999-02-16 Becton Dickinson And Company Combined spinal epidural needle set
US6285448B1 (en) 1997-05-05 2001-09-04 J. Todd Kuenstner Clinical analyte determination by infrared spectroscopy
US6050978A (en) 1997-05-09 2000-04-18 Becton Dickinson And Company Needleless valve connector
US6558351B1 (en) 1999-06-03 2003-05-06 Medtronic Minimed, Inc. Closed loop system for controlling insulin infusion
US5954643A (en) 1997-06-09 1999-09-21 Minimid Inc. Insertion set for a transcutaneous sensor
US7267665B2 (en) 1999-06-03 2007-09-11 Medtronic Minimed, Inc. Closed loop system for controlling insulin infusion
US6500150B1 (en) 1997-06-16 2002-12-31 Elan Pharma International Limited Pre-filled drug-delivery device and method of manufacture and assembly of same
US5948695A (en) 1997-06-17 1999-09-07 Mercury Diagnostics, Inc. Device for determination of an analyte in a body fluid
US6071292A (en) 1997-06-28 2000-06-06 Transvascular, Inc. Transluminal methods and devices for closing, forming attachments to, and/or forming anastomotic junctions in, luminal anatomical structures
US6115673A (en) 1997-08-14 2000-09-05 Instrumentation Metrics, Inc. Method and apparatus for generating basis sets for use in spectroscopic analysis
US7010336B2 (en) 1997-08-14 2006-03-07 Sensys Medical, Inc. Measurement site dependent data preprocessing method for robust calibration and prediction
US5858005A (en) 1997-08-27 1999-01-12 Science Incorporated Subcutaneous infusion set with dynamic needle
US6200287B1 (en) 1997-09-05 2001-03-13 Gambro, Inc. Extracorporeal blood processing methods and apparatus
US6102872A (en) 1997-11-03 2000-08-15 Pacific Biometrics, Inc. Glucose detector and method
US5964718A (en) 1997-11-21 1999-10-12 Mercury Diagnostics, Inc. Body fluid sampling device
US6036924A (en) 1997-12-04 2000-03-14 Hewlett-Packard Company Cassette of lancet cartridges for sampling blood
US5971941A (en) 1997-12-04 1999-10-26 Hewlett-Packard Company Integrated system and method for sampling blood and analysis
US6019750A (en) 1997-12-04 2000-02-01 Baxter International Inc. Sliding reconstitution device with seal
US6579690B1 (en) 1997-12-05 2003-06-17 Therasense, Inc. Blood analyte monitoring through subcutaneous measurement
AU2005399A (en) 1997-12-19 1999-07-12 Amira Medical Embossed test strip system
DE19756872B4 (de) 1997-12-19 2005-06-02 Siemens Ag Vorrichtung zur Verabreichung einer Infusion und/oder Perfusion an einen Patienten
US6244776B1 (en) 1998-01-05 2001-06-12 Lien J. Wiley Applicators for health and beauty products
SE523080C2 (sv) 1998-01-08 2004-03-23 Electrolux Ab Dockningssystem för självgående arbetsredskap
DE69838526T2 (de) 1998-02-05 2008-07-03 Biosense Webster, Inc., Diamond Bar Gerät zum Freisetzen eines Medikaments im Herzen
US6721582B2 (en) 1999-04-06 2004-04-13 Argose, Inc. Non-invasive tissue glucose level monitoring
US6728560B2 (en) 1998-04-06 2004-04-27 The General Hospital Corporation Non-invasive tissue glucose level monitoring
US6126637A (en) 1998-04-15 2000-10-03 Science Incorporated Fluid delivery device with collapsible needle cover
US6175752B1 (en) 1998-04-30 2001-01-16 Therasense, Inc. Analyte monitoring device and methods of use
US6283944B1 (en) 1998-04-30 2001-09-04 Medtronic, Inc. Infusion systems with patient-controlled dosage features
EP1078258B1 (fr) 1998-05-13 2003-07-30 Cygnus, Inc. Dispositif permettant de prevoir des valeurs de mesures physiologiques
US6662030B2 (en) 1998-05-18 2003-12-09 Abbott Laboratories Non-invasive sensor having controllable temperature feature
US6312888B1 (en) 1998-06-10 2001-11-06 Abbott Laboratories Diagnostic assay for a sample of biological fluid
US6226082B1 (en) 1998-06-25 2001-05-01 Amira Medical Method and apparatus for the quantitative analysis of a liquid sample with surface enhanced spectroscopy
US6214629B1 (en) 1998-08-06 2001-04-10 Spectral Diagnostics, Inc. Analytical test device and method for use in medical diagnoses
US6554798B1 (en) 1998-08-18 2003-04-29 Medtronic Minimed, Inc. External infusion device with remote programming, bolus estimator and/or vibration alarm capabilities
US5993423A (en) 1998-08-18 1999-11-30 Choi; Soo Bong Portable automatic syringe device and injection needle unit thereof
US6949081B1 (en) 1998-08-26 2005-09-27 Non-Invasive Technology, Inc. Sensing and interactive drug delivery
US6087182A (en) 1998-08-27 2000-07-11 Abbott Laboratories Reagentless analysis of biological samples
DE19840965A1 (de) 1998-09-08 2000-03-09 Disetronic Licensing Ag Vorrichtung zur Selbstverabreichung eines Produktfluids
US6326160B1 (en) 1998-09-30 2001-12-04 Cygnus, Inc. Microprocessors for use in a device for predicting physiological values
US6402689B1 (en) 1998-09-30 2002-06-11 Sicel Technologies, Inc. Methods, systems, and associated implantable devices for dynamic monitoring of physiological and biological properties of tumors
US6157041A (en) 1998-10-13 2000-12-05 Rio Grande Medical Technologies, Inc. Methods and apparatus for tailoring spectroscopic calibration models
WO2000030705A1 (fr) 1998-11-20 2000-06-02 Novo Nordisk A/S Aiguille a injection
US6540672B1 (en) 1998-12-09 2003-04-01 Novo Nordisk A/S Medical system and a method of controlling the system for use by a patient for medical self treatment
DE69918333T2 (de) 1998-11-30 2005-08-25 Novo Nordisk A/S SYSTEM ZUR UNTERSTüTZUNG EINER MEDIZINISCHEN SELBSTBEHANDLUNG,WELCHE EINE MEHRZAHL VON SCHRITTEN UMFASST
US6077055A (en) 1998-12-03 2000-06-20 Sims Deltec, Inc. Pump system including cassette sensor and occlusion sensor
US6128519A (en) 1998-12-16 2000-10-03 Pepex Biomedical, Llc System and method for measuring a bioanalyte such as lactate
US6200338B1 (en) 1998-12-31 2001-03-13 Ethicon, Inc. Enhanced radiopacity of peripheral and central catheter tubing
US6280381B1 (en) 1999-07-22 2001-08-28 Instrumentation Metrics, Inc. Intelligent system for noninvasive blood analyte prediction
US6531095B2 (en) 1999-02-11 2003-03-11 Careside, Inc. Cartridge-based analytical instrument with optical detector
JP2002536103A (ja) 1999-02-12 2002-10-29 シグナス， インコーポレイテッド 生物学的系に存在する分析物の頻繁な測定のためのデバイスおよび方法
US20010034023A1 (en) 1999-04-26 2001-10-25 Stanton Vincent P. Gene sequence variations with utility in determining the treatment of disease, in genes relating to drug processing
EP1048265A1 (fr) 1999-04-30 2000-11-02 V.Lilienfeld-Toal, Hermann, Prof. Dr. med. Dispositif et procédé de détection d'une substance
US6669663B1 (en) 1999-04-30 2003-12-30 Medtronic, Inc. Closed loop medicament pump
US6334851B1 (en) 1999-05-10 2002-01-01 Microfab Technologies, Inc. Method for collecting interstitial fluid from the skin
US6835553B2 (en) 1999-05-11 2004-12-28 M-Biotech, Inc. Photometric glucose measurement system using glucose-sensitive hydrogel
US6546268B1 (en) 1999-06-02 2003-04-08 Ball Semiconductor, Inc. Glucose sensor
US7806886B2 (en) 1999-06-03 2010-10-05 Medtronic Minimed, Inc. Apparatus and method for controlling insulin infusion with state variable feedback
WO2001003572A1 (fr) 1999-07-08 2001-01-18 Steffen Leonhardt Dispositif pour mesurer le taux de sucre sanguin chez l'homme
US6512937B2 (en) 1999-07-22 2003-01-28 Sensys Medical, Inc. Multi-tier method of developing localized calibration models for non-invasive blood analyte prediction
US6697654B2 (en) 1999-07-22 2004-02-24 Sensys Medical, Inc. Targeted interference subtraction applied to near-infrared measurement of analytes
US6196046B1 (en) 1999-08-25 2001-03-06 Optiscan Biomedical Corporation Devices and methods for calibration of a thermal gradient spectrometer
US6261065B1 (en) 1999-09-03 2001-07-17 Baxter International Inc. System and methods for control of pumps employing electrical field sensing
KR20010051373A (ko) 1999-11-19 2001-06-25 에섹 트레이딩 에스에이 용기의 예정된 내용물의 레벨을 감지하기 위한 센서
US6470279B1 (en) 1999-11-23 2002-10-22 James Samsoondar Method for calibrating spectrophotometric apparatus with synthetic fluids to measure plasma and serum analytes
WO2001043643A1 (fr) 1999-12-16 2001-06-21 Alza Corporation Dispositif destine a augmenter le flux transdermique de substances echantillonnees
US6477901B1 (en) 1999-12-21 2002-11-12 Integrated Sensing Systems, Inc. Micromachined fluidic apparatus
US6648821B2 (en) 2000-01-21 2003-11-18 Medtronic Minimed, Inc. Microprocessor controlled ambulatory medical apparatus with hand held communication device
US6895263B2 (en) 2000-02-23 2005-05-17 Medtronic Minimed, Inc. Real time self-adjusting calibration algorithm
US6751490B2 (en) 2000-03-01 2004-06-15 The Board Of Regents Of The University Of Texas System Continuous optoacoustic monitoring of hemoglobin concentration and hematocrit
US6375627B1 (en) 2000-03-02 2002-04-23 Agilent Technologies, Inc. Physiological fluid extraction with rapid analysis
US6572542B1 (en) 2000-03-03 2003-06-03 Medtronic, Inc. System and method for monitoring and controlling the glycemic state of a patient
EP1267961A2 (fr) 2000-03-28 2003-01-02 Elan Pharma International Limited Dispositif servant a mesurer un volume de medicament
US6485465B2 (en) 2000-03-29 2002-11-26 Medtronic Minimed, Inc. Methods, apparatuses, and uses for infusion pump fluid pressure and force detection
IT1314759B1 (it) 2000-05-08 2003-01-03 Menarini Farma Ind Strumentazione per la misura ed il controllo del contenuto di glucosiolattato o altri metaboliti in fluidi biologici
AU2001261618A1 (en) 2000-05-18 2001-11-26 Argose, Inc. Pre-and post-processing of spectral data for calibration using multivariate analysis techniques
US6699221B2 (en) 2000-06-15 2004-03-02 Vincent L. Vaillancourt Bloodless catheter
US6475196B1 (en) 2000-08-18 2002-11-05 Minimed Inc. Subcutaneous infusion cannula
US6633772B2 (en) 2000-08-18 2003-10-14 Cygnus, Inc. Formulation and manipulation of databases of analyte and associated values
IL138073A0 (en) 2000-08-24 2001-10-31 Glucon Inc Photoacoustic assay and imaging system
JP2004521667A (ja) 2000-09-08 2004-07-22 インシュレット コーポレイション 患者の輸液のための装置、システム及び方法
US6575905B2 (en) 2000-09-22 2003-06-10 Knobbe, Lim & Buckingham Method and apparatus for real-time estimation of physiological parameters
US6553841B1 (en) 2000-09-26 2003-04-29 Helix Technology Corporation Pressure transducer assembly
AU2001292946A1 (en) 2000-09-26 2002-04-08 Advantage 3D Llc Method and system for generation, storage and distribution of omni-directional object views
EP1332440B1 (fr) 2000-10-04 2012-04-11 Insulet Corporation Ensemble de collecte de donnees destine a un systeme de transfusion de patient
US8715177B2 (en) 2000-10-06 2014-05-06 Ip Holdings, Inc. Intelligent drug delivery appliance
DE60126325T2 (de) 2000-11-09 2007-11-08 Insulet Corp., Beverly Gerät zur transkutanen abgabe von medikamenten
US6645142B2 (en) 2000-12-01 2003-11-11 Optiscan Biomedical Corporation Glucose monitoring instrument having network connectivity
US20020076354A1 (en) 2000-12-01 2002-06-20 Cohen David Samuel Apparatus and methods for separating components of particulate suspension
US6560471B1 (en) 2001-01-02 2003-05-06 Therasense, Inc. Analyte monitoring device and methods of use
JP4996015B2 (ja) 2001-03-12 2012-08-08 メディキット株式会社 留置用カテーテル
US7043288B2 (en) 2002-04-04 2006-05-09 Inlight Solutions, Inc. Apparatus and method for spectroscopic analysis of tissue to detect diabetes in an individual
US6574490B2 (en) 2001-04-11 2003-06-03 Rio Grande Medical Technologies, Inc. System for non-invasive measurement of glucose in humans
US7139598B2 (en) 2002-04-04 2006-11-21 Veralight, Inc. Determination of a measure of a glycation end-product or disease state using tissue fluorescence
US7756558B2 (en) 2004-05-24 2010-07-13 Trutouch Technologies, Inc. Apparatus and methods for mitigating the effects of foreign interferents on analyte measurements in spectroscopy
US6865408B1 (en) 2001-04-11 2005-03-08 Inlight Solutions, Inc. System for non-invasive measurement of glucose in humans
US6748250B1 (en) 2001-04-27 2004-06-08 Medoptix, Inc. Method and system of monitoring a patient
US6837988B2 (en) 2001-06-12 2005-01-04 Lifescan, Inc. Biological fluid sampling and analyte measurement devices and methods
US6890291B2 (en) 2001-06-25 2005-05-10 Mission Medical, Inc. Integrated automatic blood collection and processing unit
US20030208113A1 (en) 2001-07-18 2003-11-06 Mault James R Closed loop glycemic index system
US6544212B2 (en) 2001-07-31 2003-04-08 Roche Diagnostics Corporation Diabetes management system
US6687620B1 (en) 2001-08-01 2004-02-03 Sandia Corporation Augmented classical least squares multivariate spectral analysis
US6788965B2 (en) 2001-08-03 2004-09-07 Sensys Medical, Inc. Intelligent system for detecting errors and determining failure modes in noninvasive measurement of blood and tissue analytes
WO2003016882A1 (fr) 2001-08-14 2003-02-27 Purdue Research Foundation Mesure d'une substance dans un echantillon biologique
US20040147034A1 (en) 2001-08-14 2004-07-29 Gore Jay Prabhakar Method and apparatus for measuring a substance in a biological sample
US6678542B2 (en) 2001-08-16 2004-01-13 Optiscan Biomedical Corp. Calibrator configured for use with noninvasive analyte-concentration monitor and employing traditional measurements
WO2003023356A2 (fr) 2001-09-07 2003-03-20 Argose, Inc. Dispositif de surveillance du glucose non invasif et portatif
US6740072B2 (en) 2001-09-07 2004-05-25 Medtronic Minimed, Inc. System and method for providing closed loop infusion formulation delivery
US8152789B2 (en) 2001-10-23 2012-04-10 Medtronic Minimed, Inc. System and method for providing closed loop infusion formulation delivery
US6827702B2 (en) 2001-09-07 2004-12-07 Medtronic Minimed, Inc. Safety limits for closed-loop infusion pump control
FI20011918A0 (fi) 2001-10-01 2001-10-01 Mirhava Ltd Automaattinen verisuoni yhteyden hallintalaite
JP2005504985A (ja) 2001-10-09 2005-02-17 グルコン インク 物質の電磁波吸収の測定方法とその装置
US7061593B2 (en) 2001-11-08 2006-06-13 Optiscan Biomedical Corp. Device and method for in vitro determination of analyte concentrations within body fluids
US7050157B2 (en) 2001-11-08 2006-05-23 Optiscan Biomedical Corp. Reagent-less whole-blood glucose meter
US6989891B2 (en) 2001-11-08 2006-01-24 Optiscan Biomedical Corporation Device and method for in vitro determination of analyte concentrations within body fluids
US6958809B2 (en) 2001-11-08 2005-10-25 Optiscan Biomedical Corporation Reagent-less whole-blood glucose meter
WO2003045233A1 (fr) 2001-11-21 2003-06-05 Optiscan Biomedical Corporation Procede et dispositif pour ameliorer la precision de mesures de concentration d'analyte a des sites de ponction autres que le doigt (ast)
US6862534B2 (en) 2001-12-14 2005-03-01 Optiscan Biomedical Corporation Method of determining an analyte concentration in a sample from an absorption spectrum
US7009180B2 (en) 2001-12-14 2006-03-07 Optiscan Biomedical Corp. Pathlength-independent methods for optically determining material composition
US7204823B2 (en) 2001-12-19 2007-04-17 Medtronic Minimed, Inc. Medication delivery system and monitor
US6985870B2 (en) 2002-01-11 2006-01-10 Baxter International Inc. Medication delivery system
CA2418399A1 (fr) 2002-02-11 2003-08-11 Bayer Healthcare, Llc Dispositif non invasif de dosage d'analytes dans les fluides corporels
US20030212379A1 (en) 2002-02-26 2003-11-13 Bylund Adam David Systems and methods for remotely controlling medication infusion and analyte monitoring
US6878136B2 (en) 2002-02-28 2005-04-12 Medical Product Specialists Huber needle with anti-rebound safety mechanism
US20080172026A1 (en) 2006-10-17 2008-07-17 Blomquist Michael L Insulin pump having a suspension bolus
US7500949B2 (en) 2002-03-01 2009-03-10 Medtronic Minimed, Inc. Multilumen catheter
GB0206792D0 (en) 2002-03-22 2002-05-01 Leuven K U Res & Dev Normoglycemia
US7027848B2 (en) 2002-04-04 2006-04-11 Inlight Solutions, Inc. Apparatus and method for non-invasive spectroscopic measurement of analytes in tissue using a matched reference analyte
US6960192B1 (en) 2002-04-23 2005-11-01 Insulet Corporation Transcutaneous fluid delivery system
US20050238507A1 (en) 2002-04-23 2005-10-27 Insulet Corporation Fluid delivery device
US6758835B2 (en) 2002-05-01 2004-07-06 Medtg, Llc Disposable needle assembly having sensors formed therein permitting the simultaneous drawing and administering of fluids and method of forming the same
US7175606B2 (en) 2002-05-24 2007-02-13 Baxter International Inc. Disposable medical fluid unit having rigid frame
US20040010207A1 (en) 2002-07-15 2004-01-15 Flaherty J. Christopher Self-contained, automatic transcutaneous physiologic sensing system
US7018360B2 (en) 2002-07-16 2006-03-28 Insulet Corporation Flow restriction system and method for patient infusion device
US7278983B2 (en) 2002-07-24 2007-10-09 Medtronic Minimed, Inc. Physiological monitoring device for controlling a medication infusion device
US8512276B2 (en) 2002-07-24 2013-08-20 Medtronic Minimed, Inc. System for providing blood glucose measurements to an infusion device
US7404796B2 (en) 2004-03-01 2008-07-29 Becton Dickinson And Company System for determining insulin dose using carbohydrate to insulin ratio and insulin sensitivity factor
CA2498722A1 (fr) 2002-09-12 2004-03-25 Children's Hospital Medical Center Procede et dispositif d'injection indolore de medicament
US20040051368A1 (en) 2002-09-17 2004-03-18 Jimmy Caputo Systems and methods for programming pumps
US7144384B2 (en) 2002-09-30 2006-12-05 Insulet Corporation Dispenser components and methods for patient infusion device
US7128727B2 (en) 2002-09-30 2006-10-31 Flaherty J Christopher Components and methods for patient infusion device
US7025744B2 (en) 2002-10-04 2006-04-11 Dsu Medical Corporation Injection site for male luer or other tubular connector
CN1859943B (zh) 2002-10-11 2010-09-29 贝克顿·迪金森公司 用于控制患者体内葡萄糖的浓度的系统
US7029443B2 (en) 2002-10-21 2006-04-18 Pacesetter, Inc. System and method for monitoring blood glucose levels using an implantable medical device
US7248912B2 (en) 2002-10-31 2007-07-24 The Regents Of The University Of California Tissue implantable sensors for measurement of blood solutes
US6931328B2 (en) 2002-11-08 2005-08-16 Optiscan Biomedical Corp. Analyte detection system with software download capabilities
US20040133166A1 (en) 2002-11-22 2004-07-08 Minimed Inc. Methods, apparatuses, and uses for infusion pump fluid pressure and force detection
US7142814B2 (en) 2002-12-11 2006-11-28 Shary Nassimi Automatic Bluetooth inquiry mode headset
US20040122353A1 (en) 2002-12-19 2004-06-24 Medtronic Minimed, Inc. Relay device for transferring information between a sensor system and a fluid delivery system
US7811231B2 (en) 2002-12-31 2010-10-12 Abbott Diabetes Care Inc. Continuous glucose monitoring system and methods of use
KR100521855B1 (ko) 2003-01-30 2005-10-14 최수봉 무선교신이 가능한 인슐린펌프 제어방법
US7354429B2 (en) 2003-05-27 2008-04-08 Integrated Sensing Systems, Inc. Device and method for detecting and treating chemical and biological agents
US8016798B2 (en) 2003-02-24 2011-09-13 Integrated Sensing Systems, Inc. Fluid delivery system and sensing unit therefor
US9872890B2 (en) 2003-03-19 2018-01-23 Paul C. Davidson Determining insulin dosing schedules and carbohydrate-to-insulin ratios in diabetic patients
JP4091865B2 (ja) 2003-03-24 2008-05-28 日機装株式会社 薬剤注入装置
US20040204868A1 (en) 2003-04-09 2004-10-14 Maynard John D. Reduction of errors in non-invasive tissue sampling
US7271912B2 (en) 2003-04-15 2007-09-18 Optiscan Biomedical Corporation Method of determining analyte concentration in a sample using infrared transmission data
AU2004230483A1 (en) 2003-04-15 2004-10-28 Optiscan Biomedical Corporation Sample element for use in material analysis
CN101410146A (zh) 2003-04-18 2009-04-15 因苏雷特公司 输液泵遥控器的用户接口及其使用方法
US20040241736A1 (en) 2003-05-21 2004-12-02 Hendee Shonn P. Analyte determinations
US7258673B2 (en) 2003-06-06 2007-08-21 Lifescan, Inc Devices, systems and methods for extracting bodily fluid and monitoring an analyte therein
JP2007511252A (ja) 2003-06-09 2007-05-10 ニプロ ダイアビティーズ システムズ，インコーポレイテッド 注入ポンプにおけるカップリングシステム
US8066639B2 (en) 2003-06-10 2011-11-29 Abbott Diabetes Care Inc. Glucose measuring device for use in personal area network
WO2005007223A2 (fr) 2003-07-16 2005-01-27 Sasha John Systemes et procedes d'administration programmable de medicaments pour l'administration de fluides et de concentrations multiples
US7591801B2 (en) 2004-02-26 2009-09-22 Dexcom, Inc. Integrated delivery device for continuous glucose sensor
CA2538038C (fr) 2003-09-11 2015-10-27 Theranos, Inc. Dispositif medical permettant de surveiller un analyte et de distribuer des medicaments
DE10346167A1 (de) 2003-10-01 2005-05-25 Merck Patent Gmbh Glänzende schwarze Interferenzpigmente
US7320676B2 (en) 2003-10-02 2008-01-22 Medtronic, Inc. Pressure sensing in implantable medical devices
KR100567837B1 (ko) 2003-10-24 2006-04-05 케이제이헬스케어 주식회사 혈당측정이 가능한 이동통신단말기와 결합되는 인슐린펌프와, 인슐린 펌프의 제어정보 전송을 위한 네트워크시스템
WO2005051170A2 (fr) 2003-11-19 2005-06-09 Dexcom, Inc. Recepteur integre pour capteur d'analyte en continu
EP2329763B1 (fr) 2003-12-09 2017-06-21 DexCom, Inc. Traitement de signal pour capteur d'analyte continu
US20050137573A1 (en) 2003-12-19 2005-06-23 Animas Corporation System, method, and communication hub for controlling external infusion device
WO2005089103A2 (fr) 2004-02-17 2005-09-29 Therasense, Inc. Procede et systeme de communication de donnees dans un systeme de controle et de gestion de glucose en continu
CA2559083C (fr) 2004-03-08 2015-06-16 Ichor Medical Systems, Inc. Appareil ameliore pour une administration electriquement mediee d'agents therapeutiques
EP1735729A2 (fr) 2004-03-26 2006-12-27 Novo Nordisk A/S Dispositif de preparation de donnees
US20060009727A1 (en) 2004-04-08 2006-01-12 Chf Solutions Inc. Method and apparatus for an extracorporeal control of blood glucose
US20080051764A1 (en) 2004-04-19 2008-02-28 Board Of Regents, The University Of Texas System Physiological Monitoring With Continuous Treatment
WO2005110601A1 (fr) 2004-05-07 2005-11-24 Optiscan Biomedical Corporation Element d'echantillonnage muni d'un separateur
WO2005113036A1 (fr) 2004-05-13 2005-12-01 The Regents Of The University Of California Procede et dispositif de regulation du glucose et de dosage de l'insuline pour des sujets diabetiques
US20050261660A1 (en) 2004-05-24 2005-11-24 Choi Soo B Method for controlling insulin pump using Bluetooth protocol
WO2006017121A2 (fr) 2004-07-13 2006-02-16 Waters Investments Limited Unite de commande de pompe a haute pression
US7291107B2 (en) 2004-08-26 2007-11-06 Roche Diagnostics Operations, Inc. Insulin bolus recommendation system
US20070191716A1 (en) 2004-09-29 2007-08-16 Daniel Goldberger Blood monitoring system
US20060229531A1 (en) 2005-02-01 2006-10-12 Daniel Goldberger Blood monitoring system
US7608042B2 (en) 2004-09-29 2009-10-27 Intellidx, Inc. Blood monitoring system
AU2005299929A1 (en) 2004-10-21 2006-05-04 Optiscan Biomedical Corporation Method and apparatus for determining an analyte concentration in a sample having interferents
EP1843805A4 (fr) 2004-11-09 2015-05-06 Angiotech Pharm Inc Revetement d'aiguille antimicrobien pour perfusion prolongee
CN100541234C (zh) 2004-12-21 2009-09-16 纳幕尔杜邦公司 用于在基材上形成图案化氟聚合物膜的方法
US20060167350A1 (en) 2005-01-27 2006-07-27 Monfre Stephen L Multi-tier method of developing localized calibration models for non-invasive blood analyte prediction
US7547281B2 (en) 2005-02-01 2009-06-16 Medtronic Minimed, Inc. Algorithm sensor augmented bolus estimator for semi-closed loop infusion system
US8251907B2 (en) 2005-02-14 2012-08-28 Optiscan Biomedical Corporation System and method for determining a treatment dose for a patient
US7785258B2 (en) 2005-10-06 2010-08-31 Optiscan Biomedical Corporation System and method for determining a treatment dose for a patient
US20060200070A1 (en) 2005-02-14 2006-09-07 Callicoat David N Method and apparatus for calibrating an analyte detection system with a calibration sample
US20060194325A1 (en) 2005-02-14 2006-08-31 Gable Jennifer H Fluid handling cassette with a fluid control interface
US20060189926A1 (en) 2005-02-14 2006-08-24 Hall W D Apparatus and methods for analyzing body fluid samples
US20070083160A1 (en) 2005-10-06 2007-04-12 Hall W D System and method for assessing measurements made by a body fluid analyzing device
US20060204535A1 (en) 2005-02-25 2006-09-14 Johnson Johnnie M Cell-friendly cannula and needle
US20090054753A1 (en) 2007-08-21 2009-02-26 Mark Ries Robinson Variable Sampling Interval for Blood Analyte Determinations
WO2007059476A2 (fr) 2005-11-15 2007-05-24 Luminous Medical, Inc. Determination d'analytes sanguins
JP5001934B2 (ja) 2005-04-15 2012-08-15 バイエル・ヘルスケア・エルエルシー 体内グルコースを測定する非侵襲的システム及び方法
US20060253085A1 (en) 2005-05-06 2006-11-09 Medtronic Minimed, Inc. Dual insertion set
WO2006124716A2 (fr) 2005-05-13 2006-11-23 Trustees Of Boston University Systeme de controle entierement automatise du diabete de type 1
US7509156B2 (en) 2005-05-18 2009-03-24 Clarian Health Partners, Inc. System for managing glucose levels in patients with diabetes or hyperglycemia
EP1888144B1 (fr) 2005-05-26 2009-12-09 Infusion Systems, LLC Dispositif implantable pour perfusion comprenant de multiples sorties fluidiques regulables
EP1728468A1 (fr) 2005-06-04 2006-12-06 Roche Diagnostics GmbH Évaluation de valeurs de concentration du glucose sanguin pour adaptation du dosage d'insuline
US20060276771A1 (en) 2005-06-06 2006-12-07 Galley Paul J System and method providing for user intervention in a diabetes control arrangement
US20070060869A1 (en) 2005-08-16 2007-03-15 Tolle Mike C V Controller device for an infusion pump
US7766829B2 (en) 2005-11-04 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
US7704457B2 (en) 2005-11-18 2010-04-27 Patton Charles J Automatic, field portable analyzer using discrete sample aliquots
US20080200838A1 (en) 2005-11-28 2008-08-21 Daniel Goldberger Wearable, programmable automated blood testing system
US20070129690A1 (en) 2005-12-02 2007-06-07 Joel Rosenblatt Catheter with polymeric coating
US8666760B2 (en) 2005-12-30 2014-03-04 Carefusion 303, Inc. Medication order processing and reconciliation
US20070173974A1 (en) 2006-01-25 2007-07-26 Chyi-Yeu Lin Device and method for interacting with autonomous robot
KR101414762B1 (ko) 2006-02-17 2014-07-14 알랜 엘 부츠만 카테터 세정 장치
US20070197163A1 (en) 2006-02-23 2007-08-23 Research In Motion Limited Combination modes for network connection management
US8478557B2 (en) 2009-07-31 2013-07-02 Abbott Diabetes Care Inc. Method and apparatus for providing analyte monitoring system calibration accuracy
US20070249007A1 (en) 2006-04-20 2007-10-25 Rosero Spencer Z Method and apparatus for the management of diabetes
CN101490537A (zh) 2006-05-09 2009-07-22 马自达公司 利用光衍射的自动分析仪
US20070282269A1 (en) 2006-05-31 2007-12-06 Seattle Medical Technologies Cannula delivery apparatus and method for a disposable infusion device
US7920907B2 (en) 2006-06-07 2011-04-05 Abbott Diabetes Care Inc. Analyte monitoring system and method
EP2037983A1 (fr) 2006-06-30 2009-03-25 Novo Nordisk A/S Dispositif de perfusion avec compensation d'une infusion médicale pendant la durée du port
US7736338B2 (en) 2006-08-23 2010-06-15 Medtronic Minimed, Inc. Infusion medium delivery system, device and method with needle inserter and needle inserter device and method
EP2063762A1 (fr) 2006-09-06 2009-06-03 Medingo Ltd. Système de délivrance de fluides à détection optique du niveau de concentration d'analytes
US9056165B2 (en) 2006-09-06 2015-06-16 Medtronic Minimed, Inc. Intelligent therapy recommendation algorithm and method of using the same
US8561614B2 (en) 2006-09-28 2013-10-22 Covidien Lp Multi-layer cuffs for medical devices
GB2443260C (en) 2006-10-26 2017-11-29 Cellnovo Ltd Micro-valve
GB2443261B (en) 2006-10-26 2009-04-22 Starbridge Systems Ltd Wax micro actuator
US8377040B2 (en) 2006-11-06 2013-02-19 Becton, Dickinson And Company Extravascular system venting
US20080214919A1 (en) 2006-12-26 2008-09-04 Lifescan, Inc. System and method for implementation of glycemic control protocols
US7946985B2 (en) 2006-12-29 2011-05-24 Medtronic Minimed, Inc. Method and system for providing sensor redundancy
US7734323B2 (en) 2007-01-24 2010-06-08 Smiths Medical Asd, Inc. Correction factor testing using frequent blood glucose input
US20080228056A1 (en) 2007-03-13 2008-09-18 Michael Blomquist Basal rate testing using frequent blood glucose input
WO2008124478A1 (fr) 2007-04-04 2008-10-16 Pronia Medical Systems, Llc Systèmes, procédés et programme informatique destinés à une meilleure gestion de procédures médicales pour des patients suivant des protocoles médicaux
US20080269723A1 (en) 2007-04-25 2008-10-30 Medtronic Minimed, Inc. Closed loop/semi-closed loop therapy modification system
US20080269714A1 (en) 2007-04-25 2008-10-30 Medtronic Minimed, Inc. Closed loop/semi-closed loop therapy modification system
EP2150297A1 (fr) 2007-04-30 2010-02-10 Medtronic MiniMed, Inc. Introduction d'aiguille et raccord d'écoulement de fluide pour un système d'administration de milieu d'infusion
US8417311B2 (en) 2008-09-12 2013-04-09 Optiscan Biomedical Corporation Fluid component analysis system and method for glucose monitoring and control
US8221345B2 (en) 2007-05-30 2012-07-17 Smiths Medical Asd, Inc. Insulin pump based expert system
ES2576639T3 (es) * 2007-06-20 2016-07-08 F.Hoffmann-La Roche Ag Método y dispositivo para evaluar la relación de hidratos de carbono con respecto a insulina
DK2171625T3 (en) 2007-06-21 2018-11-19 Hoffmann La Roche METHOD AND DEVICE FOR PREVENTING HYPOGLYCYMA
US8078787B2 (en) 2007-06-22 2011-12-13 Apple Inc. Communication between a host device and an accessory via an intermediate device
KR101423807B1 (ko) 2007-06-27 2014-07-30 에프. 호프만-라 로슈 아게 환자 생리학의 모델링에 기초하여 환자 맞춤형 치료를 개발하는 시스템 및 방법
US20090036753A1 (en) * 2007-07-31 2009-02-05 King Allen B Continuous glucose monitoring-directed adjustments in basal insulin rate and insulin bolus dosing formulas
US7717903B2 (en) 2007-09-06 2010-05-18 M2 Group Holdings, Inc. Operating an infusion pump system
US7935076B2 (en) 2007-09-07 2011-05-03 Asante Solutions, Inc. Activity sensing techniques for an infusion pump system
US20090069743A1 (en) 2007-09-11 2009-03-12 Baxter International Inc. Infusion therapy sensor system
MX2010002936A (es) 2007-09-17 2010-08-09 Satish Sundar Controlador de bomba de infusion de alta precision.
US8197240B2 (en) 2007-10-02 2012-06-12 Emerson Climate Technologies, Inc. Compressor having improved valve plate
WO2009049252A1 (fr) 2007-10-10 2009-04-16 Optiscan Biomedical Corporation Système d'analyse de composant de fluide et procédé pour contrôler et réguler le glucose
DE102007049446A1 (de) 2007-10-16 2009-04-23 Cequr Aps Katheter-Einführeinrichtung
US7695434B2 (en) 2007-10-19 2010-04-13 Lifescan Scotland, Ltd. Medical device for predicting a user's future glycemic state
US20100262117A1 (en) 2007-11-02 2010-10-14 University Of Virginia Patent Foundation Predictive control based system and method for control of insulin delivery in diabetes using glucose sensing
CN101925372B (zh) 2007-11-21 2013-09-11 梅丁格有限公司 分析物监测和流体分配系统
WO2009066287A2 (fr) 2007-11-21 2009-05-28 Medingo Ltd. Surveillance optique hypodermique d'un analyte corporel
US7918825B2 (en) 2007-11-29 2011-04-05 Insulet Corporation Interfacing a prefilled syringe with an infusion pump to fill the infusion pump
WO2009075925A1 (fr) 2007-12-13 2009-06-18 Shaya Steven A Procédé et appareil destinés à calculer les facteurs de sensibilité intervenant dans la glycémie chez les diabétiques
US9839395B2 (en) 2007-12-17 2017-12-12 Dexcom, Inc. Systems and methods for processing sensor data
DE112009005510B4 (de) 2008-01-31 2025-10-09 Fisher-Rosemount Systems, Inc. Robuster adaptiver modellprädiktiver Regler mit Abstimmung zum Ausgleich einer Modellfehlanpassung
EP2359880A3 (fr) 2008-02-04 2011-09-21 Nilimedix Ltd. Système d'administration de médicaments doté d'un moniteur sans fil
US20090221890A1 (en) 2008-02-28 2009-09-03 Daniel Saffer Diabetes Management System
WO2009109344A1 (fr) 2008-03-03 2009-09-11 Roche Diagnostics Gmbh Pompe à insuline avec des capacités de remplacement
US8466185B2 (en) 2008-03-12 2013-06-18 Biocrine Ab Methods and assays for detecting and treating hypoglycemia
DK3260145T3 (da) 2008-04-09 2020-02-17 Hoffmann La Roche Fluidniveausensor til et modulopbygget, hudklæbbart system til medicinsk fluidlevering
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
US8140275B2 (en) * 2008-07-18 2012-03-20 Insulet Corporation Calculating insulin on board for extended bolus being delivered by an insulin delivery device
US8734422B2 (en) 2008-08-31 2014-05-27 Abbott Diabetes Care Inc. Closed loop control with improved alarm functions
US8622988B2 (en) 2008-08-31 2014-01-07 Abbott Diabetes Care Inc. Variable rate closed loop control and methods
EP2323720A4 (fr) 2008-09-09 2013-04-10 Pulmonx Corp Systèmes et procédés pour inhiber la pénétration d'un flux de sécrétions dans un cathéter d'évaluation fonctionnelle
GB2464114B (en) 2008-10-02 2012-06-13 Cellnovo Ltd Linear capacitive displacement sensor
US9409052B2 (en) 2008-10-03 2016-08-09 Adidas Ag Program products, methods, and systems for providing location-aware fitness monitoring services
US8632497B2 (en) 2008-10-09 2014-01-21 Roche Diagnostics Operations Inc. Skin securable drug delivery device with a shock absorbing protective shield
US20100174228A1 (en) 2008-10-24 2010-07-08 Bruce Buckingham Hypoglycemia prediction and control
US8613719B2 (en) 2008-11-03 2013-12-24 Calibra Medical, Inc. Dosage sensing unit with tactile feedback
US8352290B2 (en) 2008-11-07 2013-01-08 Curlin Medical Inc. Method of automatically programming an infusion pump
US9370621B2 (en) 2008-12-16 2016-06-21 Medtronic Minimed, Inc. Needle insertion systems and methods
US9375529B2 (en) 2009-09-02 2016-06-28 Becton, Dickinson And Company Extended use medical device
CN102395310A (zh) 2009-02-26 2012-03-28 莫尔研究应用有限公司 用于自动监控糖尿病相关治疗的方法以及系统
GR1007310B (el) 2009-03-09 2011-06-10 Αχιλλεας Τσουκαλης Εμφυτευσιμος βιοαισθητηρας με αυτοματη βαθμονομηση
US8172798B2 (en) 2009-05-12 2012-05-08 Sigma International General Medical Apparatus LLC System and method for managing infusion therapies
WO2010135638A2 (fr) 2009-05-22 2010-11-25 Abbott Diabetes Care Inc. Procédés pour réduire l'occurrence de fausses alarmes hypoglycémiques
EP2432377A1 (fr) 2009-05-22 2012-03-28 Abbott Diabetes Care, Inc. Caractéristiques ergonomiques pour système de délivrance d'insuline intégré
US8257300B2 (en) 2009-05-22 2012-09-04 Abbott Diabetes Care Inc. Safety features for integrated insulin delivery system
EP2435962B1 (fr) 2009-05-29 2023-04-19 University of Virginia Patent Foundation Coordinateur de système et architecture modulaire pour une régulation en boucle ouverte et en boucle fermée du diabète
US9687194B2 (en) 2009-06-17 2017-06-27 Medtronic Minimed, Inc. Closed-loop glucose and/or insulin control system
EP3284494A1 (fr) 2009-07-30 2018-02-21 Tandem Diabetes Care, Inc. Système de pompe à perfusion portable
US8547239B2 (en) 2009-08-18 2013-10-01 Cequr Sa Methods for detecting failure states in a medicine delivery device
US8900190B2 (en) 2009-09-02 2014-12-02 Medtronic Minimed, Inc. Insertion device systems and methods
ES2730101T3 (es) 2009-09-08 2019-11-08 Hoffmann La Roche Dispositivos, sistemas y procedimientos para ajustar los parámetros de administración de líquido
US20110099507A1 (en) 2009-10-28 2011-04-28 Google Inc. Displaying a collection of interactive elements that trigger actions directed to an item
US9858386B2 (en) 2009-11-02 2018-01-02 Universita Degli Studi Di Padova Method to recalibrate continuous glucose monitoring data on-line
JP5595513B2 (ja) 2009-11-12 2014-09-24 アカシア ファーマ リミテッド 口腔乾燥症の治療のためのベタネコールの使用
US20110124996A1 (en) 2009-11-20 2011-05-26 Roche Diagnostics Operations, Inc. Diabetes health management systems and methods
CA2786258C (fr) 2009-12-31 2018-10-23 Deka Products Limited Partnership Ensemble pompe a perfusion
US8348898B2 (en) 2010-01-19 2013-01-08 Medimop Medical Projects Ltd. Automatic needle for drug pump
DK2525863T3 (en) 2010-01-20 2019-01-21 Hoffmann La Roche METHOD AND DEVICE FOR IMPROVING Glycemic Control
US10911515B2 (en) 2012-05-24 2021-02-02 Deka Products Limited Partnership System, method, and apparatus for electronic patient care
US9662438B2 (en) 2010-02-05 2017-05-30 Deka Products Limited Partnership Devices, methods and systems for wireless control of medical devices
BR112012019658A2 (pt) 2010-02-05 2016-05-03 Sanofi Aventis Deutschland mecanismo de travamento para uso com um dispositivo de entrga de fármaco, módulo medicado e dispositivo de entrega de fármaco
IL211800A (en) 2010-03-21 2014-03-31 Isaac Zukier Liquid or clot injection device
US8810394B2 (en) 2010-04-16 2014-08-19 Medtronic, Inc. Reservoir monitoring for implantable fluid delivery devices
WO2011156373A1 (fr) 2010-06-07 2011-12-15 Amgen Inc. Dispositif d'administration de médicament
DK2397181T3 (da) 2010-06-18 2014-03-31 Hoffmann La Roche Indføringsindretning med et permanent låseligt og drejeligt nåle-dækorgan
US20110313680A1 (en) 2010-06-22 2011-12-22 Doyle Iii Francis J Health Monitoring System
CA2808457C (fr) 2010-08-17 2018-09-04 University Of Florida Research Foundation, Inc. Systeme intelligent d'administration de medicament et/ou de fluide, destine a optimiser un traitement medical ou une therapie au moyen de donnees pharmacodynamiques et/ou pharmaco cinetiques
US9132233B2 (en) 2010-08-26 2015-09-15 B. Braun Melsungen Ag Infusion control device
US9498573B2 (en) 2010-09-24 2016-11-22 Perqflo, Llc Infusion pumps
EP2436412A1 (fr) 2010-10-04 2012-04-04 Unomedical A/S Canule d'arroseur
WO2012051344A2 (fr) 2010-10-12 2012-04-19 Regents Of The University Of California, The Maintien de zones physiologiques définies multiples utilisant un contrôle prédictif de modèle
US8707392B2 (en) 2010-10-15 2014-04-22 Roche Diagnostics Operations, Inc. Systems and methods for disease management
US9211378B2 (en) 2010-10-22 2015-12-15 Cequr Sa Methods and systems for dosing a medicament
CA3080222C (fr) 2011-02-09 2023-06-13 Becton, Dickinson And Company Dispositif de perfusion a insertion et retraction automatique d'aiguille d'intubateur
US8852152B2 (en) 2011-02-09 2014-10-07 Asante Solutions, Inc. Infusion pump systems and methods
CA2826745C (fr) 2011-02-09 2021-03-16 Becton, Dickinson And Company Dispositif d'insertion pliable pour trousse de perfusion pour administration de medicament
EP2673040B1 (fr) 2011-02-09 2022-03-30 Becton, Dickinson and Company Ensemble de perfusion d'insuline
US10136845B2 (en) 2011-02-28 2018-11-27 Abbott Diabetes Care Inc. Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same
AU2012223282B2 (en) 2011-03-01 2017-02-02 Nutrition 21, Llc Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders
WO2012122520A1 (fr) 2011-03-10 2012-09-13 Abbott Diabetes Care Inc. Dispositif de surveillance de substance à analyser à fonctions multiples et procédés d'utilisation
US8844007B2 (en) 2011-04-08 2014-09-23 Dexcom, Inc. Systems and methods for processing and transmitting sensor data
US20120271655A1 (en) 2011-04-19 2012-10-25 Yishai Knobel Methods and Systems for Enabling Applications on a Mobile Computing Device to Access Data Associated with a Peripheral Medical Device
US8308680B1 (en) 2011-04-26 2012-11-13 Medtronic Minimed, Inc. Selective alarms for an infusion device
EP2712407A4 (fr) 2011-05-05 2015-06-03 Eksigent Technologies Llc Système et procédé de commande de pression différentielle d'une pompe électrocinétique à mouvement alternatif
US9075900B2 (en) 2011-05-18 2015-07-07 Exco Intouch Systems, methods and computer program products for providing compliant delivery of content, applications and/or solutions
EP2723229B1 (fr) 2011-06-23 2018-09-26 University Of Virginia Patent Foundation Plateforme unifiée pour la surveillance et la régulation des niveaux de glucose dans le sang chez des patients diabétiques
EP2782630B1 (fr) 2011-11-22 2019-09-25 Becton, Dickinson and Company Système d'administration de médicament pourvu d'un mécanisme à retard
CA3012939C (fr) 2011-12-07 2020-07-21 Becton, Dickinson And Company Ensembles de protection d'aiguille et dispositifs de perfusion a utiliser avec ceux-ci
US20130178791A1 (en) 2012-01-09 2013-07-11 Jonathan C. Javitt Method and system for detecting and treating biological and chemical warfare agents
CA2866624C (fr) 2012-03-07 2022-06-28 Deka Products Limited Partnership Ensemble pompe a perfusion
US9463280B2 (en) 2012-03-26 2016-10-11 Medimop Medical Projects Ltd. Motion activated septum puncturing drug delivery device
HUE067982T2 (hu) 2012-03-30 2024-12-28 Insulet Corp Folyadékadagoló készülék transzkután beviteli eszközzel, behelyezõ mechanizmussal és vércukor monitorozással
US20150174209A1 (en) 2012-05-25 2015-06-25 Amylin Pharmaceuticals. Llc Insulin-pramlintide compositions and methods for making and using them
EP2858699A1 (fr) 2012-06-09 2015-04-15 Roche Diagnostics GmbH Élément d'introduction jetable destiné à être utilisé avec un dispositif médical
US20130338576A1 (en) 2012-06-15 2013-12-19 Wayne C. Jaeschke, Jr. Portable infusion pump with pressure and temperature compensation
US10159787B2 (en) 2012-06-18 2018-12-25 Fresenius Kabi Deutschland Gmbh Port cannula system for puncturing port catheters
US9757510B2 (en) 2012-06-29 2017-09-12 Animas Corporation Method and system to handle manual boluses or meal events for closed-loop controllers
US10130767B2 (en) 2012-08-30 2018-11-20 Medtronic Minimed, Inc. Sensor model supervisor for a closed-loop insulin infusion system
KR102147838B1 (ko) 2012-08-30 2020-08-26 메드트로닉 미니메드 인코포레이티드 폐쇄-루프 인슐린 주입 시스템을 위한 보호 기술
AU2015200834B2 (en) 2012-08-30 2016-07-14 Medtronic Minimed, Inc. Safeguarding techniques for a closed-loop insulin infusion system
US9878096B2 (en) 2012-08-30 2018-01-30 Medtronic Minimed, Inc. Generation of target glucose values for a closed-loop operating mode of an insulin infusion system
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US20150213217A1 (en) 2012-09-13 2015-07-30 Parkland Center For Clinical Innovation Holistic hospital patient care and management system and method for telemedicine
CN109963271B (zh) 2012-11-12 2022-06-03 埃姆皮公司 用于电刺激的无线配对和通信的系统及方法
US9253433B2 (en) 2012-11-27 2016-02-02 International Business Machines Corporation Method and apparatus for tagging media with identity of creator or scene
TWM452390U (zh) 2012-12-11 2013-05-01 Dongguan Masstop Liquid Crystal Display Co Ltd 主動式電容觸控筆
US20140276536A1 (en) 2013-03-14 2014-09-18 Asante Solutions, Inc. Infusion Pump System and Methods
US9907909B2 (en) 2012-12-20 2018-03-06 Animas Corporation Method and system for a hybrid control-to-target and control-to-range model predictive control of an artificial pancreas
WO2014109898A1 (fr) 2013-01-14 2014-07-17 The Regents Of University Of California Technique de personnalisation basée sur un modèle d'un pancréas artificiel pour applications de diabète de type i
KR102212020B1 (ko) 2013-01-14 2021-02-05 더 리전트 오브 더 유니버시티 오브 캘리포니아 제1형 당뇨병 응용을 위한 인공 췌장에 대한 모델 예측 제어 문제에서의 일주기 목표-구역 조절
US10573413B2 (en) 2013-03-14 2020-02-25 Roche Diabetes Care, Inc. Method for the detection and handling of hypoglycemia
US10016561B2 (en) * 2013-03-15 2018-07-10 Tandem Diabetes Care, Inc. Clinical variable determination
US9795737B2 (en) 2013-03-15 2017-10-24 Animas Corporation Method and system for closed-loop control of an artificial pancreas
EP2973095B1 (fr) 2013-03-15 2018-05-09 Animas Corporation Modèle temps-action d'insuline
SG11201507417RA (en) 2013-03-15 2015-10-29 Amgen Inc Body contour adaptable autoinjector device
WO2014172467A1 (fr) 2013-04-16 2014-10-23 Smartloop Llc Systèmes et procédés d'administration d'insuline discrétionnaire
US10003545B2 (en) 2013-04-26 2018-06-19 Roche Diabetes Care, Inc. Mobile phone application for diabetes care with medical feature activation
CN108704191B (zh) 2013-05-31 2021-02-05 西兰制药公司 具有可插入式预填充筒的流体输送装置
EP3011487B1 (fr) 2013-06-21 2023-09-27 Fresenius Vial SAS Procédé et dispositif de commande pour commander l'administration d'insuline à un patient
US20150025329A1 (en) 2013-07-18 2015-01-22 Parkland Center For Clinical Innovation Patient care surveillance system and method
WO2015009385A1 (fr) 2013-07-19 2015-01-22 Dexcom, Inc. Optimiseur de taux de base à moyenne temporelle
WO2015021441A1 (fr) * 2013-08-09 2015-02-12 Alere San Diego, Inc. Dosage et méthode de détermination d'insuline active
WO2015056259A1 (fr) 2013-10-14 2015-04-23 Dreamed-Diabetes Ltd. Système et procédé pour une gestion améliorée de pancréas artificiel
EP2862586B1 (fr) 2013-10-21 2021-09-01 F. Hoffmann-La Roche AG Unité de commande pour unités de pompe à perfusion comprenant une unité d'intervention contrôlée
US10517892B2 (en) 2013-10-22 2019-12-31 Medtronic Minimed, Inc. Methods and systems for inhibiting foreign-body responses in diabetic patients
US9847038B2 (en) 2013-10-31 2017-12-19 Dexcom, Inc. Adaptive interface for continuous monitoring devices
US10311972B2 (en) 2013-11-11 2019-06-04 Icu Medical, Inc. Medical device system performance index
AU2014349078B2 (en) 2013-11-14 2019-07-25 Regents Of The University Of California Glucose rate increase detector: a meal detection module for the health monitoring system
DK3074073T3 (da) 2013-12-01 2019-05-13 Becton Dickinson Co Indretning til et lægemiddel
US9849240B2 (en) 2013-12-12 2017-12-26 Medtronic Minimed, Inc. Data modification for predictive operations and devices incorporating same
US20150173674A1 (en) 2013-12-20 2015-06-25 Diabetes Sentry Products Inc. Detecting and communicating health conditions
WO2015097792A1 (fr) 2013-12-25 2015-07-02 富士通株式会社 Appareil, procédé et programme d'appariement
US9486571B2 (en) 2013-12-26 2016-11-08 Tandem Diabetes Care, Inc. Safety processor for wireless control of a drug delivery device
WO2015103543A1 (fr) 2014-01-03 2015-07-09 University Of Virginia Patent Foundation Noeud d'échange de données central pour surveiller un système et vérifier des taux de glucose dans le sang chez des patients diabétiques
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
US9898585B2 (en) 2014-01-31 2018-02-20 Aseko, Inc. Method and system for insulin management
US9399096B2 (en) 2014-02-06 2016-07-26 Medtronic Minimed, Inc. Automatic closed-loop control adjustments and infusion systems incorporating same
WO2015136513A1 (fr) 2014-03-14 2015-09-17 HUGHES, John Pascal Dispositif de surveillance
US10034976B2 (en) 2014-03-24 2018-07-31 Medtronic Minimed, Inc. Fluid infusion patch pump device with automatic fluid system priming feature
CN106456067A (zh) 2014-06-06 2017-02-22 德克斯康公司 基于数据和背景的故障判别和响应处理
US9656017B2 (en) 2014-06-20 2017-05-23 Howard E. Greene Infusion delivery devices and methods
AU2015284181B2 (en) 2014-06-30 2020-05-07 Icu Medical, Inc. Infusion pump error display
JP2017525451A (ja) 2014-08-01 2017-09-07 ベクトン・ディキンソン・アンド・カンパニーＢｅｃｔｏｎ， Ｄｉｃｋｉｎｓｏｎ Ａｎｄ Ｃｏｍｐａｎｙ 連続的なグルコースのモニタリングをする投入装置
AU2015301146B2 (en) 2014-08-06 2020-06-25 Regents Of The University Of California Moving-horizon state-initializer for control applications
US9717845B2 (en) 2014-08-19 2017-08-01 Medtronic Minimed, Inc. Geofencing for medical devices
DK3185934T3 (en) 2014-08-28 2018-10-01 Unl Holdings Llc SKIN SENSORS FOR PHARMACEUTICAL ADMINISTRATION DEVICES
CN106687160B (zh) 2014-09-15 2020-10-30 赛诺菲 具有脱离传感器的皮肤可附接药物注射装置
US20160082187A1 (en) 2014-09-23 2016-03-24 Animas Corporation Decisions support for patients with diabetes
US10529454B2 (en) 2014-10-17 2020-01-07 Bradley E. Kahlbaugh Human metabolic condition management
US9636453B2 (en) 2014-12-04 2017-05-02 Medtronic Minimed, Inc. Advance diagnosis of infusion device operating mode viability
US9943645B2 (en) 2014-12-04 2018-04-17 Medtronic Minimed, Inc. Methods for operating mode transitions and related infusion devices and systems
US10307535B2 (en) 2014-12-19 2019-06-04 Medtronic Minimed, Inc. Infusion devices and related methods and systems for preemptive alerting
US9775957B2 (en) 2015-01-16 2017-10-03 Becton, Dickinson And Company Smart module for injection devices
CN111905188B (zh) 2015-02-18 2022-07-22 英赛罗公司 流体输送和输注装置及其使用方法
WO2016141082A1 (fr) 2015-03-02 2016-09-09 Unitract Syringe Pty Ltd Dispositif et procédé d'obtention de raccords aseptiques
US10449298B2 (en) * 2015-03-26 2019-10-22 Medtronic Minimed, Inc. Fluid injection devices and related methods
US10617363B2 (en) 2015-04-02 2020-04-14 Roche Diabetes Care, Inc. Methods and systems for analyzing glucose data measured from a person having diabetes
US10646650B2 (en) 2015-06-02 2020-05-12 Illinois Institute Of Technology Multivariable artificial pancreas method and system
EP3314548B1 (fr) 2015-06-28 2021-10-06 The Regents of The University of California Commande prédictive de modèle de pondération de la vitesse d'un pancréas artificiel pour des applications pour le diabète de type 1
US10463297B2 (en) 2015-08-21 2019-11-05 Medtronic Minimed, Inc. Personalized event detection methods and related devices and systems
JP6976259B2 (ja) 2015-11-04 2021-12-08 バイエル・ヘルスケア・エルエルシーBayer HealthCare LLC バーコードデータベースおよびソフトウェア更新システム
EP3380061B1 (fr) 2015-11-24 2025-04-09 Insulet Corporation Système d'administration de médicament automatisé portable
WO2017091584A1 (fr) 2015-11-25 2017-06-01 Insulet Corporation Dispositif portable de distribution de médicament
US10248839B2 (en) 2015-11-30 2019-04-02 Intel Corporation Locating objects within depth images
WO2017105600A1 (fr) 2015-12-18 2017-06-22 Dexcom, Inc. Rétro-saisie de données destinées au suivi continu du glucose
JP2019509770A (ja) 2016-01-05 2019-04-11 ビッグフット バイオメディカル インコーポレイテッドＢｉｇｆｏｏｔ Ｂｉｏｍｅｄｉｃａｌ， Ｉｎｃ． 動作するマルチモーダル薬剤デリバリ・システム
US9980140B1 (en) 2016-02-11 2018-05-22 Bigfoot Biomedical, Inc. Secure communication architecture for medical devices
US10792423B2 (en) 2016-04-13 2020-10-06 The Trustees Of The University Of Pennsylvania Methods, systems, and computer readable media for physiology parameter-invariant meal detection
US20200268968A1 (en) 2016-04-22 2020-08-27 Children`S Medical Center Corporation Methods and systems for managing diabetes
WO2017192397A1 (fr) 2016-05-02 2017-11-09 Dexcom, Inc. Système et procédé destinés à fournir des alertes optimisées à un utilisateur
US10363374B2 (en) 2016-05-26 2019-07-30 Insulet Corporation Multi-dose drug delivery device
US10332632B2 (en) 2016-06-01 2019-06-25 Roche Diabetes Care, Inc. Control-to-range failsafes
WO2018009614A1 (fr) 2016-07-06 2018-01-11 President And Fellows Of Harvard College Commande prédictive de modèle déclenché par événement pour systèmes de pancréas artificiel intégrés
US10052441B2 (en) 2016-08-02 2018-08-21 Becton, Dickinson And Company System and method for measuring delivered dose
US11202579B2 (en) 2016-08-08 2021-12-21 Zoll Medical Corporation Wrist-worn device for coordinating patient care
EP4120151A1 (fr) 2016-09-09 2023-01-18 Dexcom, Inc. Procédé permettant la configuration d'un calculateur de bolus par un professionnel de santé
US10987032B2 (en) 2016-10-05 2021-04-27 Cláudio Afonso Ambrósio Method, system, and apparatus for remotely controlling and monitoring an electronic device
US10561788B2 (en) 2016-10-06 2020-02-18 Medtronic Minimed, Inc. Infusion systems and methods for automated exercise mitigation
US11097051B2 (en) 2016-11-04 2021-08-24 Medtronic Minimed, Inc. Methods and apparatus for detecting and reacting to insufficient hypoglycemia response
US10854324B2 (en) 2016-12-21 2020-12-01 Medtronic Minimed, Inc. Infusion systems and methods for prospective closed-loop adjustments
WO2018120104A1 (fr) 2016-12-30 2018-07-05 Medtrum Technologies Inc. Système et procédé de commande en boucle fermée dans un pancréas artificiel
US10583250B2 (en) 2017-01-13 2020-03-10 Bigfoot Biomedical, Inc. System and method for adjusting insulin delivery
EP4708311A2 (fr) 2017-01-13 2026-03-11 Insulet Corporation Procédés, systèmes et dispositifs d'administration d'insuline
US10881793B2 (en) 2017-01-13 2021-01-05 Bigfoot Biomedical, Inc. System and method for adjusting insulin delivery
JP2020507841A (ja) 2017-01-17 2020-03-12 カレオ，インコーポレイテッド 無線接続及び事象検出を伴う薬剤送達デバイス
US11197949B2 (en) 2017-01-19 2021-12-14 Medtronic Minimed, Inc. Medication infusion components and systems
US20200046268A1 (en) 2017-02-15 2020-02-13 University Of Virginia Patent Foundation System, method, and computer readable medium for a basal rate profile adaptation algorithm for closed-loop artificial pancreas systems
JP6929673B2 (ja) 2017-03-21 2021-09-01 テルモ株式会社 算出装置、送液装置、及びインスリン投与システム
US10729849B2 (en) 2017-04-07 2020-08-04 LifeSpan IP Holdings, LLC Insulin-on-board accounting in an artificial pancreas system
US11147920B2 (en) 2017-04-18 2021-10-19 Lifescan Ip Holdings, Llc Diabetes management system with automatic basal and manual bolus insulin control
CA3198598A1 (fr) * 2017-05-05 2018-11-08 Eli Lilly And Company Regulation en boucle fermee de glucose physiologique
US11116898B2 (en) 2017-06-26 2021-09-14 Abbott Diabetes Care Inc. Artificial pancreas integrated CGM architectures and designs
WO2019077482A1 (fr) 2017-10-19 2019-04-25 Mor Research Applications Ltd. Système et méthode destinés à être utilisés dans la gestion d'un traitement thérapeutique
EP3707820A4 (fr) 2017-11-08 2021-08-11 General Vibration Corporation Commutation et modulation de phase cohérentes d'un réseau d'actionneurs linéaires
US11197964B2 (en) 2017-12-12 2021-12-14 Bigfoot Biomedical, Inc. Pen cap for medication injection pen having temperature sensor
WO2019125932A1 (fr) 2017-12-21 2019-06-27 Eli Lilly And Company Régulation en boucle fermée de glucose physiologique
EP3788628B1 (fr) 2018-05-04 2024-12-11 Insulet Corporation Contraintes de sécurité pour un système d'administration de médicament basé sur un algorithme de commande
CN112313754A (zh) 2018-06-22 2021-02-02 伊莱利利公司 胰岛素和普兰林肽输送系统、方法和设备
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
AU2018264051B2 (en) 2018-08-09 2020-03-26 Final Bell Brand Co. A vaporization device, method of using the device, a charging case, a kit, and a vibration assembly
US11628251B2 (en) 2018-09-28 2023-04-18 Insulet Corporation Activity mode for artificial pancreas system
US11097052B2 (en) 2018-09-28 2021-08-24 Medtronic Minimed, Inc. Insulin infusion device with configurable target blood glucose value for automatic basal insulin delivery operation
US10894126B2 (en) 2018-09-28 2021-01-19 Medtronic Minimed, Inc. Fluid infusion system that automatically determines and delivers a correction bolus
WO2020081393A1 (fr) 2018-10-15 2020-04-23 President And Fellows Of Harvard College Modèle témoin pour pancréas artificiel
MX2022000670A (es) 2019-07-16 2022-05-20 Beta Bionics Inc Sistema de control de glucosa en sangre.
US12555660B2 (en) 2019-08-02 2026-02-17 Abbott Diabetes Care Inc. Systems, devices, and methods relating to medication dose guidance
US11935637B2 (en) 2019-09-27 2024-03-19 Insulet Corporation Onboarding and total daily insulin adaptivity
WO2022020197A1 (fr) 2020-07-22 2022-01-27 Insulet Corporation Paramètres de base pour l'administration d'insuline en boucle ouverte fondée sur des enregistrements d'administration d'insuline

Also Published As

Publication number Publication date
WO2021113647A1 (fr) 2021-06-10
EP4354455A3 (fr) 2024-07-10
EP4354455B1 (fr) 2025-10-29
EP4657456A2 (fr) 2025-12-03
EP4354455C0 (fr) 2025-10-29
EP4657456A3 (fr) 2026-03-11
US20240252753A1 (en) 2024-08-01
EP4354455A2 (fr) 2024-04-17
US20210170104A1 (en) 2021-06-10
US11957875B2 (en) 2024-04-16
EP4069082A1 (fr) 2022-10-12

Similar Documents

Publication Publication Date Title
US12121700B2 (en) Open-loop insulin delivery basal parameters based on insulin delivery records
AU2024202189B2 (en) Blood glucose rate of change modulation of meal and correction insulin bolus quantity
US20240252753A1 (en) Techniques and devices providing adaptivity and personalization in diabetes treatment
US20240058534A1 (en) Techniques for improved automatic drug delivery performance using delivery tendencies from past delivery history and use patterns
EP4231308B1 (fr) Durée adaptative d'action de l'insuline destinée à être utilisée dans des calculs d'insuline à bord
US20210228804A1 (en) Meal insulin determination for improved post prandial response
KR20230113361A (ko) 자동 약물 전달 시스템을 위한 간단한 식사 알림을위한 디바이스 및 방법
US20230062884A1 (en) Devices and methods for controlling drug dosage delivery for automatically providing a drug to a patient
EP4476738A1 (fr) Techniques de détermination de facteurs de correction de médicaments dans des systèmes d'administration automatique de médicaments
EP4080516B1 (fr) Système amélioré d'administration automatique de médicament pour individus atteints de diabète de type 2
US20220249773A1 (en) Techniques and devices for adaptation of maximum drug delivery limits
US20250295854A1 (en) Accuracy of basal delivery amounts

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220624

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20240109

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602020032094

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20240605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240906

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240905

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240906

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240905

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1691826

Country of ref document: AT

Kind code of ref document: T

Effective date: 20240605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241007

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241007

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241005

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241005

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602020032094

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

26N No opposition filed

Effective date: 20250306

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20241204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240605

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20241231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20241231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20241231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20241204

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20251211

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20251219

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20251229

Year of fee payment: 6

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20201204